Building predictive unbound brain-to-plasma concentration ratio (Kp,uu,brain) models by Varadharajan, Srinidhi
Master’s degree project in Bioinformatics 
Department of Biology, Lund University 
 
 
Building predictive  
unbound brain-to-plasma 
concentration ratio (Kp,uu,brain) models 
 
 
 
Srinidhi Varadharajan 
August 2013-May 2014
  
 
Table of Contents 
ABSTRACT ............................................................................................................................................ 1 
1. INTRODUCTION .......................................................................................................................... 2 
1.1 Background ............................................................................................................................... 2 
1.2 Drug discovery process ............................................................................................................. 3 
1.3 Challenges in CNS drug discovery ........................................................................................... 4 
1.4 Barriers in the brain................................................................................................................... 5 
1.5 Measurement of brain exposure ................................................................................................ 8 
1.6 In-silico QSAR models ............................................................................................................. 9 
1.7 In silico BBB penetration models ........................................................................................... 12 
1.8  Kp,uu,brain Models ...................................................................................................................... 14 
1.9 The goal of current thesis work ............................................................................................... 15 
2. METHODS ....................................................................................................................................... 16 
2.1. Dataset .................................................................................................................................... 16 
2.2 Molecular descriptors .............................................................................................................. 16 
2.3 Modeling methods .................................................................................................................. 17 
2.4 Model building workflow ....................................................................................................... 20 
2.5 Model Validation .................................................................................................................... 22 
2.6 Model Interpretation ............................................................................................................... 24 
3. RESULTS AND DISCUSSIONS ................................................................................................. 25 
3.1 Compounds in the dataset ....................................................................................................... 25 
3.2 Validation of the Current Kp,uu,brain model ................................................................................ 27 
3.3  Signature SVM model built on the old dataset ...................................................................... 30 
3.4  Single component models ...................................................................................................... 32 
3.5  Consensus Models: ................................................................................................................ 37 
3.6  Conformal Prediction ............................................................................................................. 42 
3.7  Kp,brain Modeling approach ...................................................................................................... 46 
3.9  Kp,uu,brain Model Interpretation ................................................................................................. 48 
3.10 Descriptor analysis for the individual components (Kp,brain, Vu,brain and fu,p) .......................... 56 
4. CONCLUSION AND FUTURE PERSPECTIVES.......................................................................... 62 
5. REFERENCES ................................................................................................................................. 63 
 
 
 1 
 
 
 
 
 
ABSTRACT 
 
The blood-brain barrier (BBB) constitutes a dynamic membrane primarily evolved to protect the brain 
from exposure to harmful xenobiotics. The distribution of synthesized drugs across the blood-brain 
barrier (BBB) is a vital parameter to consider in drug discovery projects involving a central nervous 
system (CNS) target, since the molecules should be capable of crossing the major hurdle, BBB. In 
contrast, the peripherally acting drugs have to be designed optimally to minimize brain exposure 
which could possibly result in undue side effects. It is thus important to establish the BBB 
permeability of molecules early in the drug discovery pipeline. 
Previously, most of the in-silico attempts for the prediction of brain exposure have relied on the total 
drug distribution between the blood plasma and the brain. However, it is now understood that the 
unbound brain-to-plasma concentration ratio (             is the parameter that precisely indicates the 
BBB availability of compounds.           describes the free drug concentration of the drug 
molecule in the brain, which, according to the free drug hypothesis, is the parameter that causes the 
relevant pharmacological response at the target site. 
Current work involves revisiting a model built in 2011 and uploaded in an in-house server and 
checking for its performance on the data collected since then.  This gave a satisfying result showing 
the stability of the model.  The old dataset was then further extended with the temporal dataset in 
order to update the model. This is important to maintain a substantial chemical space so as to ensure a 
good predictability with unknown data. Using other methods and descriptors not used in the previous 
study, a further improvement in the model performance was achieved. Attempts were also made in 
order to interpret the model by identifying the most influential descriptors in the model.  
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1. INTRODUCTION 
1.1 Background 
Trends and technologies associated with Drug discovery and development have experienced 
an upsurge over the last few decades. Being an interdisplinary field of research, this area has 
seen some profound expansion in the knowledge base with the improvements in 
understanding of basic chemistry, genetics, and molecular biology and so on. The sequencing 
of human genome was one such advancement that further opened up the prospects by aiding 
in the discovery of new targets. These advancements have led to a lot of success stories in 
treating various diseases.   
One of the major advancements in the field of pharmaceutical research can be pointed out as 
the advanced computational technologies that are now being employed in all major stages of 
the drug discovery process. These have been shown to considerably reduce resources and 
time and limit chemical synthesis of undesirable compounds. 
The drug discovery and development is in general a long, tedious and expensive process 
coupled with a high risk of failure. Typically, it takes around 15-20 years to develop a drug 
from the initial stages of target identification till the introduction of the drug into the market. 
The cost of introducing a drug molecule into the market has been approximated to be almost 
$1.2 billion. 
[1]
 U.S. Food and Drug Administration (FDA) estimates that eventually only 8% 
of the compounds that enter the Phase 1 clinical trials can reach the market.
 [2] 
Though the investment in the pharmaceutical research has increased through the years, 
associated developmental cost of drugs also seems to be accruing 
[3]
 while the number of 
approved drugs has reduced owing to the tighter regulatory requirements for the drug 
approval. A lot of efforts have been made to address the fundamental issue of reducing 
attrition while also speeding up the process of drug development.  
Traditionally, in the early phases of drug discovery, the focus was mainly on the efficacy and 
the selectivity of the molecule towards the target. The pharmacokinetics and ADMET 
(Absorption, Distribution, Metabolism, Excretion and Toxicology) studies were usually 
carried out later in the later phase. Through the years, some studies had indicated that a major 
portion of drug attrition is attributable to poor ADMET properties.
 [4]
 This called for a need to 
move towards the ‘Fail fast Fail cheap’ strategy by investigating the ADME properties in 
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early phases of drug discovery.
 [5]
 The cost associated increases as a compound progresses 
through the drug development cascade. 
[6]
 
To reduce the late-stage attrition, it is critical to identify compounds that are unlikely to 
succeed and to terminate the development of these as early as possible. Only the compounds 
exhibiting a good ADMET profile should be advanced into the clinical trials thus reducing 
the resources spent.  
Computational models are one of the attractive solutions for predicting the appropriate 
ADME characteristics of molecules under consideration. These approaches can be used as a 
cost effective filter for choosing compounds that are most likely to meet the desired needs
 [7]
, 
even before their actual synthesis. 
1.2 Drug discovery process 
Historically random experiments were designed by trial and error basis to find novel drugs 
[8]
. 
With the extensive efforts in understanding molecular biology, chemistry, biochemistry, 
genetics and so on, in context of human body and various related functions, the process of 
discovering drugs has become much more streamlined and continues to improve. 
Traditional linear model of drug discovery and development processes starts off with defining 
the disease to be investigated in the project. This is followed by identification of a target 
involved in the disease using various genomics and proteomics analysis and then followed by 
the validation of the identified target. A druggable target is usually a biological component 
like enzymes, receptors etc which can bind to the ligand and elicit the required response.  
Once a suitable target has been identified, thousands and millions of compounds are screened 
for an interaction with the target to discover “hit” compounds which serve as the starting 
compounds for the drug development process. The hit compounds are then progressed into 
the lead identification, validation and optimization phase. During this phase the compounds 
that can interact with the chosen target are then assessed for various properties like selectivity 
and affinity using biochemical assays. Potency of the compounds is also determined. This 
phase involves multitude of in-vitro/in-vivo screening assays to determine and confirm the 
characteristics of the molecule. The techniques like structure activity relationships (SARs) 
and ADMET studies are carried out to evaluate the development potential of the lead 
compounds. 
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After the initial selection of lead compounds series, optimization work is done to improve the 
efficacy and safety of the chosen compounds. Structural variations of the lead series are often 
performed at this stage to tailor the molecule for desired qualities. These analogues are then 
tested using various assays to find the best compound to serve as a drug candidate. 
The next step involves studying the effects of the drug candidate in animal models. In this 
stage the safety and efficacy of the candidate molecule is further studied and pharmacokinetic 
profiles of the molecule is established in the animal models. Drug toxicity profiles are 
extensively evaluated using in-vitro and in-vivo assays. High levels of safety have to be 
established before the human trials in the next phase. The above mentioned steps are referred 
to as pre-clinical research where the safety and efficacy of the drug molecule is established 
prior to its advancement towards the clinical trials. 
Clinical research is the final phase which involves various phases where the drug molecule is 
tested in human. After a drug molecule successfully passes these phases, the approval for the 
new drug is sought from the regulatory agencies. Once approved, the drug can eventually 
reach the market. However, the follow-up clinical studies still need to be conducted in of 
form of post-marketing investigations.  
1.3 Challenges in CNS drug discovery 
Many Central nervous system (CNS) diseases do not have effective drugs in the market. Most 
small molecule CNS drugs in the market are focused on certain therapeutic areas like 
migraine, epilepsy etc., while leaving some of the other common, often devastating CNS 
disease with no effective cure.
 [9]
 There is a great unmet need in the area of neurodegenerative 
diseases like Alzheimer's disease, Parkinson's disease and so on. 
[10]
 In many instances, 
despite identification of some promising molecules, the complexity of CNS has kept them 
much away from becoming successful drugs. On the other hand, targeting CNS might also be 
necessary in certain non-CNS diseases. 
CNS drug candidates have been observed to have a lower success rate and longer 
development phases, as compared to their non-CNS counterparts. 
[11]
 This difference can be 
largely associated with the numerous complexities involved in targeting CNS, like the 
intricacies of the human brain, lower predictability of animal models, CNS side effects and so 
on.
[11]
 This area thus entails a careful investigational research of alternate approaches for 
increasing the success rate. 
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In drug discovery phase, it is very essential to determine the possibility of a molecule to cross 
the blood-brain barrier. The drugs targeted to CNS must successfully permeate the BBB to 
achieve an optimal distribution to the brain. The peripherally acting drugs, on the other hand, 
may have to be kept away from the brain to avoid unwanted toxic effects. This necessitates a 
better understanding of the complexities that surround BBB and the properties of molecules 
that can increase or decrease the permeation. 
Various in-vivo and in-vitro experiments have been designed for the determination of extent 
of brain penetration for drugs. However, these methods are quite time-consuming and costly. 
Computational methods to predict molecular properties will be very useful in initial screening 
so as to make a good decision of which compounds can go forward to the more laborious and 
expensive tests involved in in-vivo and in-vitro studies. 
[12]
 
1.4 Barriers to access the brain 
Existence of physiological barriers that separate CNS from the systemic blood circulation has 
been well established. Two vital barriers in the CNS are the blood-brain barrier (BBB) and 
the blood-cerebrospinal fluid barrier (BCSFB). The former acts as a barrier between the 
blood and brain interstitial fluid (ISF) and is composed of brain capillary endothelial cells 
with tight junctions.  The latter is present at the choroid plexus, separating blood and 
ventricular cerebrospinal fluid (CSF) 
[13]
 and is formed of epithelial cells linked by tight 
junctions which are however more permeable than the BBB. 
[14]
 The BCSFB is found to have 
a relatively much smaller surface area as compared to the BBB, thus BBB is thought to play 
the major role in drug delivery. 
[15]
 Various metabolic enzymes and transporters are also 
present to shield/protect the brain from endogenous toxins and various other xenobiotics.  
1.4.1 The blood brain barrier 
BBB presents the major hurdle for a drug to reach a target in brain.  It primarily functions to 
regulate the transport of compounds to and from the brain for protecting it from harmful 
xenobiotics and other potential neurotoxins. It has been observed that almost 98% of the 
small molecules do not cross the BBB. 
[16]
 BBB is thus crucial to maintain homeostasis in the 
CNS.
 
The existence of such a barrier in the brain was first realized in the 19
th
 century through the 
experiments performed by Paul Ehrlich. 
[17]
 BBB has been actively under research and 
scientists are attempting to gain deeper understanding of the complexities. 
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The structural feature that is of primary importance in BBB is the tight junctions that exist 
between capillary endothelial cells. These effectively restrict inter-cellular transfer of solutes. 
The tight junctions are characterized by absence of fenestrations and usually display a low 
pinocytosis.
[18]
 Efflux transporters are another defense mechanisms flaunted by the BBB. 
They serve to pump toxins and xenobiotics out of the brain. BBB has also been observed to 
show a high electrical resistance, it thus keeps polar and ionic molecules, especially the acid 
compounds, away from penetrating into the brain. 
[19]
 
1.4.2 Transportation of molecules across the BBB 
Usually transport of compounds across the BBB occur transcellularly as the paracellular 
transportation is restricted by the presence of tight junctions. However, transcellular mode of 
transport is further affected by various efflux transports present at the BBB. There are various 
mechanisms that occur at BBB influence the brain permeation of compounds.  
Passive diffusion 
Most commonly, compounds enter the brain by passive diffusion, where the concentration 
gradient is the main driving force. Equilibrium is attained when the concentration of the drug 
compound at either side of the membrane are equal
 [20]
. The capacity of the drug to passively 
permeate depends on its physicochemical properties. For example, lipophilicity has been 
identified to be a key factor for diffusion of drug into the brain. It is seen that an increases in 
lipophilicity usually corresponds to a higher BBB permeation. Other properties like 
molecular weight, polar surface area etc, also play a vital role. 
Carrier mediated transport 
Various transporters are present at the BBB evolved to function in effectively protecting the 
brain. Some of the compounds that are hydrophilic and cannot undergo passive diffusion use 
transporters to aid the permeation process.  
Influx transporters are involved in transport of molecules like glucose, amino acids from 
blood to brain 
[21] 
to provide
 
the nutrients required by the brain. These mainly aid the 
transport of small hydrophilic molecules which can otherwise not pass through the BBB by 
passive diffusion.  
Efflux transporters are a very critical defense system evolved at the BBB. They serve the 
gatekeeper function by pumping out the potentially toxic compounds from the brain. The 
most important efflux transporters at BBB are P-glycoprotein (P-gp), breast cancer resistance 
protein (BCRP) and multidrug resistance protein (MRP). 
[22]
 They fall into the ABC (ATP-
binding cassette) superfamily.
 [23]
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1.4.3 Characteristics of molecules that can potentially cross BBB  
Drug-like molecules ought to have a good bioavailability, ADMET properties and potency. 
Druglikeness has often been defined based on “Rule of Five” proposed by Lipinski[84], which 
is a set of rules assessing the oral absorption of the compounds. The “Rule of Five” states a 
rule of thumb for a compound to possess good bioavailability, a molecular weight less than 
500; Number of hydrogen bond donors less than 5; number of hydrogen bond acceptors less 
than 10 ; a ClogP (octanol-water partition coefficient) less than 5. Compounds that do not 
exhibit the forementioned characteristics are most likely to suffer poor bioavailability. 
Similar efforts have been made by many other groups to examine the relationship between 
the molecular properties of pharmaceutically relevant compounds and their potential to 
become drugs. The purpose has been to discover trends in the physicochemical properties for 
the compound in a particular developmental stage or in a certain disease area and to identify 
the key factors for compound related attrition.  
In general CNS drugs tends to be on the higher side with respect to the lipophilicity, and 
rigidity of the molecule while they need to be smaller (lower molecular weight), and possess 
lower hydrogen-bond acceptor and donors, fewer negative charges  and a lower PSA, 
compared to the non-CNS drugs. Numerous studies have attempted to look into the molecular 
physiochemical properties related to BBB penetration. Similar to Lipinski’s “Rule of five”, 
some simple rules have been formulated to define CNS drug-likeness. 
For example, it has been proposed that the following attributes are advantageous for a 
potential lead to be able to permeate the BBB. 
[24]
 A molecular weight less than about 400-
450; number of hydrogen bond donors less than 3;number of hydrogen bond acceptors less 
than 7; a PSA of 60-70 Å
2
; pKa of 7.5-10.5 and fewer rotatable bonds.  
Lipophilicity has been known to be one of the most critical factors for the BBB permeation.  
Higher lipophilicity enables the compounds to permeate the lipid rich membranes. 
[25]
 
Lipophilicity is often expressed in terms of logP. Though a high lipophilicity is favorable, it 
is important for a molecule to possess optimal values of logP, because with the increase in 
lipophilicity the non-specific binding of the molecules to the plasma proteins also increases.   
Permeation of a compound across BBB is highly influenced by hydrogen bonding potential 
of the molecule. BBB permeation decreases significantly with increase in number of 
hydrogen bonds. 
[26]
 This necessitates that the sum of nitrogen and oxygen atoms in the 
molecule should preferably be kept below 5.
 [24]
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For the passive diffusion, it has been observed that ionization of the molecule plays an 
important role. Weak bases and neutral compounds have much higher chances of permeating 
the BBB as compared to acids. On the other hand, strong acids and bases are usually not 
capable of penetrating the BBB. 
[27]
 
1.5 Measurement of brain exposure 
1.5.1 Total brain-plasma concentration ratio (Kpb) 
The total brain-plasma concentration ratio denoted by Kp,brain or logBB  has been the most 
widely used parameter for in-silico prediction of brain exposure. It is calculated as logarithm 
of the ratio of the concentration of the drug molecule in the brain to that in blood, at 
equilibrium (Equation 1 
[28]
). It basically measures the way the drug molecule partitions itself 
between the brain and the blood. 
            (1) 
However, it has been argued that logBB, being based on total concentrations, is affected by 
the non-specific binding of the molecules to the plasma protein and brain tissue
 [29]
 and may 
be misleading 
28,31,32
 since it is only the free drug that is available for transport across BBB 
and for binding to the target proteins in the brain. 
1.5.2 Permeability solubility product 
Upon realization of the incomplete description given by the conventional analysis using 
LogBB, it was suggested to alternatively use logPS (logarithm of permeability solubility) as a 
measure of unbound molecule. The permeability solubility product measures the rate of drug 
transport over the BBB 
[33]
. It is measured by in-vitro brain perfusion experiments. However, 
this measure does not represent the free drug concentration either as it does not consider the 
efflux clearance at BBB. Furthermore, PS is a measure of penetration rate and therefore is not 
necessarily correlated with the extent of penetration. 
1. 5.3 Unbound Brain-to-plasma Concentration ratio (Kp,uu,brain)  
Unbound brain-to-plasma concentration (Kp,uu,brain) is a parameter that estimates the amount 
of free drug in the brain ISF. It is defined as the ratio of unbound drug concentration in brain 
to the unbound drug in plasma, in steady state 
[28]
(Equation 2). 
            (2) 
 
C
u,brainISF
 
K
p,brain
 =  C
u,p
 
=  K
p,uu,brain
 
Cu, brainISF 
Cu,plasma  
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Where Cu,brainISF is the free drug concentration in the ISF and Cu,plasma is the free drug 
concentration in the brain. The unbound drug concentration in brain, Cu,brainISF can be directly 
measured through microdialysis in brain[45,46]. The method is experimentally challenging and 
involves a large amount of resources to carry out. The non-specific binding associated with 
highly lipophilic molecules pose a further challenge for this method [34] and is therefore of a 
limited usability in drug discovery projects. However, an alternative method of determining 
Kp,uu,brain  has been proposed, which can be used to circumvent the problems associated with 
microdialysis[28].Where two in-vitro experiments and one in-vivo experiment are used to 
determine Kp,uu,brain.  
            (3) 
Where Kp,brain is the total brain-blood concentration ratio, Vu,brain is the unbound volume of 
distribution in brain and fu,p is the unbound fraction of drug in plasma. Vu,brain is commonly 
measured using brain-slice method
[62]
 and  fu,p is determined by equilibrium dialysis 
technique.
[85]
 
Generally it has been concluded that when Kp,uu,brain is close to 1, the compound is expected 
to be able to cross the BBB by passive diffusion and is also not  a substrate for the 
transporters at the BBB. The compounds with a Kp,uu,brain  of greater than 1 are substrates for 
the influx transporters and are thus actively transported, while the compounds that have a 
Kp,uu,brain less than 1 tend to be substrates for efflux transporters.
[35]
 
According to the eq. 3, experimental determination of Kp,uu,brain  involves measurement of the 
total brain-to-plasma concentration ratio obtained from in-vivo animal experiments and in-
vitro determination of plasma protein binding and binding to the brain tissue. Predictive in-
silico models can be of great value in circumventing the necessity of performing such 
resource and time intensive experiments. 
1.6 In-silico predictive models 
Predictive modeling has now gained popularity in the area of drug discovery. It is based on 
using algorithms that can learn from the provided examples and can later be used for the 
prediction of unseen examples.  In-silico analysis involves various statistical methods like 
multiple-linear regression, Partial least squares (PLS), machine learning methods etc. Data 
modeling often involves the well known concept of structure activity relationships. As the 
K
p,uu,brain
 =  
V
u,brain
 
K
p,brain
 
f
u,p
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name suggests, structure activity relationships refers to the method of correlating structural 
features that a molecule possesses to its biological activity.  
1. 6.1 Quantitative structure activity relationships (QSAR) 
The idea of relating the structure of a compound to its biological activity can be traced back 
to 1869, when Crum brown and Fraser proposed the concept of biological response (φ ) being 
a function of chemical structure (C) of a compound (equation 4)
[36]
. Thus a change in the 
chemical feature will alter the biological activity exhibited by the molecule. 
φ  = f ( C )           ( 4 )  
Subsequent studies further supported the view of correlating the structure with the activity of 
molecules. The essence of these methods are in the fact that the structural features of 
molecule can be used to infer physical and chemical properties of the which can in turn be 
correlated to the biological activity of the molecule.
 [37]
 Various statistical methods are thus 
used to find features that make a compound active or inactive and the relationships between 
these features and the bioactivity. These relationships can be either qualitative (SAR) or 
quantitative (QSAR). 
Quantitative structure activity relationship attempts to determine the quantitative relationship 
between the chemical features and the desired biological response. This relationship between 
the biological endpoint and the descriptors of the compound are modeled using statistical 
methods. The modern QSAR studies were initiated by Corwin Hansch around 1963. 
[66]
 
The crucial stages in building a reliable QSAR model firstly involve collection of a good 
dataset as model quality will wholly depend on the quality of the dataset. The subsequent step 
involves calculating a set of relevant descriptors that can describe the dataset well. The model 
generation then begins by choosing a suitable method to establish the correlation between the 
compounds and the calculated descriptors. Validation of the built model is then done to 
investigate the predictive powers of the model (Figure 1.1). 
1.6.2 Molecular descriptors  
A molecular descriptor is a calculated numerical representation of various properties inherent 
in a molecule.  
Several common molecular descriptors exists that represent various attributes of a structure , 
ranging from descriptors that rely on simple counts 
[38]
 of important features like hydrogen 
bond donors acceptors , number of rotatable bonds, number of a aromatic rings systems and 
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so on to more complex descriptors, for example, based on quantum  chemistry calculated 
properties.
[68]
 
Of great importance are the descriptors for describing physicochemical properties of 
molecules, such as hydrophobicity measured in terms of octanol-water partition coefficient 
etc
 [38]
. Other commonly used descriptors include topological indices, shape indices
 [38]
, 
fingerprints 
[69]
 etc.  Designing of 3D descriptors for molecules has also been an attractive 
concept to capture the properties that 2D descriptors might fail to describe. 
Molecular descriptors thus form the basis to use the properties inferred from the chemical 
structure in a mathematical setting. 
 
Figure 1.1 General workflow of a QSAR experiment. 
 
1.6.3 Machine learning algorithms 
Classical linear QSAR models often utilize linear statistical methods like Partial least squares 
(PLS) and multiple linear regression. These often suffered from the problem of over fitting 
[1]
 
and nonlinear relationships cannot be addressed well using these methods. Thus non-linear 
machine learning methods like support vector machine(SVM), random forest  (RF) provide 
an attractive solution to this problem by offering the advantage of handling large amounts of 
data more accurately.
[39]
 Machine learning is thus one of the methods commonly used to 
build QSAR models. 
Machine learning is a sub field under artificial intelligence that involves creating computer 
algorithms that can learn from data.  It basically seeks to establish relationships from the data 
by finding sensible patterns in it, which can then be used to make predictions on new 
examples. Machine learning as a technique possesses some attractive qualities when 
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compared to direct programming. It is more accurate and can process larger data more 
efficiently. 
Machine learning includes supervised and unsupervised learning methods. Supervised 
learning involves algorithms that learn complex patterns from a set of labeled examples. 
Labeled examples refer to those that have both features and the associated labels. The 
algorithm thus learns a hypothesis to fit appropriately to the dataset in consideration 
Unsupervised Learning, on the other hand involves use of Unlabelled dataset thus there are 
no associated labels. The algorithm searches for patterns within the data to make useful 
inferences. 
There are two major categories of machine learning problems, namely, classification and 
regression problems. In regression, the data consists of continuous values, and the model thus 
predicts a real value for the new example. Classification, on the other hand, deals with 
categorical data. 
1.6.4 Validation of the QSAR model 
A key point to consider about a QSAR model is its predictive power, which is indicative of 
how well the model can predict an example that it has not seen before. Determination of this 
is done through different validation methods. The validation methods can be primarily 
categorized into internal validation and external validation.  
Internal validation is used to determine the model fit, which gives an idea of how an unseen 
example might be handled by the model. Most commonly employed methods are leave one 
out cross-validation 
[65]
, k-fold cross validation
 [66]
 and so on. It is measured in terms of cross 
validated correlation coefficient or Q
2
. 
External validation refers to the use of an external test set which is not included in the dataset 
used to build the model. The performance of the model on the test set is often measured in 
terms of correlation coefficient R
2 
and RMSE. 
1.7 In silico BBB penetration models 
1.7.1 logBB Models 
Previous work in this field has often been focused on logBB predictive models for describing 
the capacity of a compound to permeate and distribute across the BBB.  Various statistical 
methods and machine learning algorithms have been employed for building these models. 
Studies have also analyzed dependencies of the logBB to various vital physico-chemical 
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descriptors. It has been consistently noted that logBB is mainly dependent on hydrogen 
bonding potential, molecular volume and lipophilicity
 [42]
. 
One of the initial efforts towards QSAR modeling of logBB was taken by Young et al., where 
the correlation of logBB with logP was established in 20 anti-histamine molecules. Later 
studies by Waterbeemd et al.
 [44]
, attempted to correlate logBB to molecular volume and PSA. 
Futher, Abraham et al.
 [45]
, worked on logBB model based on 60 compounds and relating 
them to five solute descriptors  The major limitation with these initial studies were the 
smaller size of dataset used.  Thus, subsequent research saw a lot of progress in such logBB 
modeling based on extending the Young dataset along with using better statistical methods. 
The size of the publicly available logBB data has increased gradually. The biggest public 
logBB set so far compiled by Lanevskij et al 
[48] 
constitutes about 400 compounds.  Diverse 
molecular descriptors have been utilized, for example, 2D physicochemical descriptors
 [49-54]
 
describing information about the molecular size, shape, lipophilicity etc., and 3D molecular 
structure 
[54, 55, 56]
. The early logBB models typically used a smaller set of descriptors to build 
the model and the model building strategy was often limited to simple MLR statistics. The 
recent studies have attempted to build models using larger number of descriptors along with 
more complex algorithms that can deal with the increased number of variables 
[42, 57, 58]
. The 
models utilizing non-linear algorithms 
[42,58]
 have, in general shown a higher accuracy than 
the linear models 
[57,58,59]
.  
 However, recently it has been realized that logBB is not very relevant for making inferences 
on BBB permeability. Thus using Kp,uu,brain data for the purpose is a much more attractive 
solution. 
1.7.2 Classification models 
Various classification models have been developed for classifying compounds based on their 
ability to cross the blood brain barrier and elicit the required effect. A common strategy has 
been to classify compound into BBB+/BBB- based on whether they are permeate through 
BBB by passive diffusion. These classification models have shown an accuracy of about 75-
95 %. 
Ajay et al., performed a study on CNS active/inactive drug to build a compound library with 
potential CNS activity. They also analyzed the difference in the CNS active and inactive 
terms of seven important descriptors like molecular weight, number of rotatable bonds, 
kappa2, logP, hydrogen bond donors and acceptors and so on. The models built in this study 
could produce upto 80% predictability. Zhang et al.,
 [42]
 performed similar studies using a 
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dataset of 156 compound and building QSAR classification models mainly employing kNN 
and SVM algorithms. These models, built on different types of descriptors like Dragon, MOE 
and MolConnZ, showed a good accuracy of prediction. 
There have been several other attempts to build classification models for BBB penetration. 
Various modeling schemes have been used for building such models. Decision tree based 
techniques like recursive partitioning 
[43] 
has also seen to have a lot of potential for this 
purpose.   
CNS+/CNS- Classification have also been extensively studied. This usually involves 
categorizing compounds based on whether they are centrally active or not.  The CNS+ 
compounds are usually BBB+, on the contrary, the BBB+ compounds do not necessarily have 
to be CNS+. The BBB+ compounds can also be CNS- which implies that they permeate the 
BBB while not showing any activity.  This makes the definitions rather simple for the 
analysis of complexities related to permeation of compounds through the BBB. 
1.8  Kp,uu,brain Models 
The published Kp,uu,brain modeling studies performed by Fridén et al 
[28]
, utilized a dataset of 
43 compounds  to build in-silico Kp,uu,brain models using PLS. Kp,uu,brain was assessed based on 
Kp,brain, Vu,brain and fu,p using Equation(3) . 
16 molecular descriptors were included in the study which comprised of standard descriptors 
like ClogP, molecular weight, hydrogen bond donors (HBD) and so on. Irrelevant descriptors 
were later excluded based on calculation of variable importance for projection score (VIP). It 
was observed that the significant descriptors as picked by the VIP scores were related mainly 
to hydrogen bonding. The model utilizing only HBA as the descriptor was found to possess 
comparable predictive power to the model utilizing the set of 16 descriptors. 
Chen et al., in 2011, extended the Fridén’s dataset to include 247 in-house compounds in total 
for Kp,uu,brain. The model was primarily built based on SVM and RF machine learning 
algorithms. Descriptor set used for the model building consists of 196 in-house descriptors. 
Modeling strategy included building an indirect model, which utilized the individual datasets 
of Kp,brain, Vu,brain and fu,p for model building and the Kp,uu,brain values then calculated from the 
individual predictions, and a direct model based on the  Kp,uu,brain data. 
Studying through various single component and consensus model, it was found that the 
consensus model with SVM direct, RF indirect and RF direct components gave the best 
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prediction with an R
2
 of 0.58 and RMSE of 0.46. It was thus seen that consensus models in 
general perform better than the single component models.   
 
1.9 The goal of  Master Thesis project 
The aim of the current master thesis project was to collect the up-to-date AstraZeneca in-
house Kp,uu,brain  data, examine the performance of previously published Kp,uu,brain model 
[39]
 on 
the temporal test dataset and build new models by using the expanded dataset. During the 
model building, various QSAR modeling strategies were used and compared. It was 
particularly interesting to apply some new QSAR methods such as the combination of 
support vector machine (SVM) and molecular signature descriptors
 [63]
 and conformal 
prediction
 [64]
 etc. on the Kp,uu,brain dataset. The work further involved examining the 
substructures within the dataset to make useful inferences about the structural features that 
have strong influence on the penetration and distribution of the molecule across the BBB. 
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2. METHODS 
2.1. Dataset 
A predictive model for Kp,uu,brain was built in 2011 based on a set of in-house data and was 
uploaded into an in house server for routine usage. This study was based on a dataset 
consisting of 248 compounds that had the values for Kp,brain, Vu,brain and fu,p . While a separate 
set of dataset consisting of other measured values of Kp,brain, Vu,brain and fu,p  consisted of  505, 
3235 and 474 compounds respectively. 
Since 2011, there has been additional data accumulated for these parameters. This dataset 
was collected and cleaned to remove duplicates and overlaps. The old dataset was then 
extended by the addition of the newly measured compounds (since 2011). This new set of 
data had 100 compounds for which the values of Kp,brain, Vu,brain and fu,p  were available. 
The present dataset compiled for the model building and validation consists of 722, 1210 and 
5756 compounds for Kp,brain, Vu,brain and fu,p  respectively while the Kp,uu,brain dataset consists of 
347 compounds in total. 
 
2.2 Molecular descriptors  
In this work, two types of molecular descriptors were employed which are described below. 
The first set, called AZ descriptors (AZdesc), an in-house descriptor set consisting of 196 2D 
and 3D descriptors describing various physico-chemical properties like molecular weight, 
lipophilicity, hydrogen bonding properties, electrostatics and topology. An in-house program, 
Clab, was used for the calculation of AZ descriptors with input of SMILES strings. 
The second type of descriptor is the signature molecular descriptors. This descriptor was 
developed by Faulon et al. It is a class of atom based descriptor based on the concept of 
molecular graph. Such a molecular graph can be expressed as G = (VG, EG), where VG 
represents the atoms in the molecule being described while EG denoted the edges which 
represents the bonds between the atoms. A molecule is thus defined in terms of a set of 
canonical sub graphs which represent all the atoms that are at a predefined distance (height) 
from the central atom in consideration. Thus, for a molecular graph represented by G and an 
atom x in that molecule, the signature of height h of x I can be denoted by hσG(x). 
Signature molecular descriptor thus explains the extended valence of the atoms of the 
molecule under consideration
 [71]
. This way of representation gives a tree structure, where the 
first layer constitutes the neighbours of the atom x in the molecular graph G and the 
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subsequent layers consist of the neighbours of the vertices of the previous layer except the 
atom x
[72]
.  Thus, each molecule under consideration is associated with a vector whose 
components are the frequency of occurrence of the particular signature in the structure of the 
molecule. The signature descriptors have been previously used successfully in various QSAR 
modeling strategy 
[71, 73]
. 
 
2.3 Modeling methods  
In the current study, for building Kp,uu,brain models, two non-linear machine learning 
algorithms were used, namely, SVM and Random Forest . 
2.3.1 Support Vector Machine 
Support vector machine (SVM) is a supervised learning algorithm that was developed by 
Vapnik and co-workers 
[73]
. It is largely based on the concepts of statistical learning or VC 
theory (developed by Vapnik and Chervonenkis) and structure risk minimization theory. It 
was originally proposed for classification but is now also widely applied in regression 
problems. Typically, the goal of SVM algorithm is to map a n-dimensional input vector into a 
high dimensional feature space and define a optimal hyperplane that can maximize the 
margin between the classes, in case of a binary classification problem. In case of Support 
vector regression the selected optimal hyperplane is the one from which the distance to all the 
data points is minimum. This mapping is done to the training examples to make it closer to a 
linearly separable case and is accomplished using a kernel function. Radial basis function is a 
commonly used type of kernel for SVM algorithm. 
SVM algorithm depends on some hyper-parameters namely, C and gamma. C refers to the 
soft margin constant. These Parameters have to be optimized based on the nature of dataset 
under consideration. This is often done by k-fold cross validation where for each split of data 
into k subsets, the cross validation error is computed using different values of C and gamma. 
The values of C and gamma corresponding to the least cross validation error are then used for 
training an SVM model. SVM is particularly attractive as it effectively addresses risk of 
overfitting. It can handle high dimensional feature space and also local minimization.  
2.3.2 Random forest  
Decision trees methods are another category of widely used machine learning algorithms. In 
this algorithm, criteria are found for splitting the dataset into branches, thus forming a tree 
structure, hence the name. Each of these branches is referred to as a node and the terminal 
nodes are called leaves of the tree. The splitting of the nodes is achieved using some decision 
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rules which once established, are used to predict the future examples. A decision tree can be 
used in case of both regression and classification. Each end node of the tree denotes 
quantitative data in the former case and categorical data in case of classification problem. 
These set of methods find a great utility owing to their ability to handle high dimensional data 
while ignoring irrelevant descriptors 
[74]
 and providing a better ease of interpretation. On the 
other hand, decision tree algorithms may be on the lower side with respect to the prediction 
accuracy. 
[74]
 
While numerous improvements have been made to such decision tree algorithms to improve 
its applicability, Random forest is one such improvement. Random forest is an ensemble 
method proposed by Leo Breiman
[75]
 which aggregates results from multiple decision tree 
based learners. A random forest is a collection of trees constructed from the training dataset 
and validated internally to be capable of yielding predictions for future observations 
[76]
. 
Every tree in the collection, called a base learner, is constructed from a bootstrap sample 
drawn with replacement from the original dataset. This random sample often comprises of 
approximately two third of the data while the remaining one third of the dataset is referred to 
as the ‘Out-of-bag' sample. The OOB sample is then run down the constructed tree for 
prediction and the error rate is computed. The main improvement in case of the random forest 
algorithm as compared to many of the previous decision tree based methods is the 
introduction of an additional layer of randomness. Instead of splitting using all the available 
variables, the RF algorithm selects only a random subset of variables to find the best split at 
each of the nodes.  The trees are then grown to the maximum levels without pruning. Finally, 
the predictions from these ensembles of trees are combined using majority voting in case of 
classification problems and average values in case of regression problems. The number of 
descriptors considered at every node is often the parameter that has to be optimized 
depending on the dataset under consideration. 
RF has been found to be very useful in cases where the number of Independent variables is 
much greater compared to the number of observations 
[76]
. Some of the other attractive 
features of random forest predictors are high predictability and speed along with an inherent 
estimation of prediction accuracy and measures of descriptors importance. Such an ability of 
determining the measures of descriptor importance is of great utility in ranking the variables 
based on their capability to predict the response from the model.  
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2.3.3 Consensus models 
Consensus model refers to a kind of data fusion which considers ways to combine predictions 
from various models. This approach, in general, has been shown to improve the predictive 
performance of a model. This improvement is probably attributable to the fact that when 
predictions from various component models are combined, the errors are averaged out and 
the methods show a greater accuracy by complimenting each other. A commonly used 
method for building consensus model is to take the average of predictions from various 
models. 
2.3.4 Conformal predictors 
Conformal predictors are a set of predictors that provide confidence for the prediction, based 
on past experience.  These can be built on any traditional algorithm. Initially developed for 
classification problems, conformal prediction is now also being applied on regression 
problems.  This method is mainly based on the usefulness of hedged predictions in analyzing 
datasets. Predictions are said to be “hedged” when they are associated with scores of how 
confident and accurate the predictor is in predicting the values. 
[77]
 
For a typical classification problem, conformal prediction associates the prediction with 
confidence and credibility values. The confidence score indicates how likely it is for the 
predicted label to be correct while credibility evaluates the suitability of the training data to 
classify the given test example. On the other hand, conformal prediction applied on a 
regression problem gives a range of confidence levels and outputs region predictions 
(intervals) which indicate a range of possible values at that confidence level. The main 
criteria to be fulfilled for being able to apply conformal prediction are that the data should 
follow the IID (independent and identically distributed). The algorithm first produces a point 
prediction and then non-conformity scores are generated which evaluate how different the 
test example is compared to the previous examples seen by the algorithm 
[78]
. This score is 
then utilized in determining the region prediction. The conformal prediction is valid if the 
probability of true label lying outside the predicted region is not more than the error  . Thus 
as the confidence level increases the width of the region increases giving rise to nested 
prediction sets. This width is a kind of measure for the efficiency. Thus there is a trade-off 
between the reliability denoted by the confidence and the accuracy. 
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2.4 Model building workflow 
In the present study, two model building approaches were defined based on the dataset being 
used, namely, direct and indirect models. 
• Direct model represents a model built using Kp,uu,brain data determined from 
experimental values of  Kp,brain, Vu,brain and fu,p  .   
• Indirect model consists of the three single component models (Kp,brain, Vu,brain and fu,p  ) 
built based on the respective experimental data, whose individual predictions on the test 
set are combined to calculate Kp,uu,brain values (using equation (3) ) .  
Strategy of building the indirect model is to be able to effectively incorporate the 
experimental data available for each of the parameters, which is comparatively more 
compared to that of the Kp,uu,brain. 
 
Figure 2.2: Kp,uu,brain Model workflow 
 
Various attempts were made to build models and improve the performance. The SVM and RF 
models with AZ descriptors were built using AZOrange 
[81]
, an in-house implementation of 
the open source package Orange 
[80]
, which is software developed for data mining. The 
models using Signature molecular descriptors were built using LIBSVM 
[79]
, an open source 
SVM library. The statistical analysis was performed using R 
[82]
 and TIBCO Spotfire. Table 
2.1 explains the main models built during this study. 
 21 
 
Table  2.1  Various Kp,uu,brain models built 
1 I.  
Signature SVM model built on  the 
old data 
O_ SVM(S,d) Signature SVM Direct model built on the old data 
2 O_ SVM(S,i) Signature SVM Indirect model built on the old data 
    
3 II.  
Single component models 
 
SVM(A, d) SVM Direct model built using AZ descriptors 
4 RF(A, d)  RF Direct model built using AZ descriptors 
5 SVM(S, d) SVM Direct model built using signature descriptors 
6 SVM(A, i) SVM Indirect model built using AZ descriptors 
7 RF(A, i) RF Indirect model built using AZ descriptors 
8 SVM(S,i) SVM Indirect model built using signature descriptors 
    
  
 
 
 
 
 
 
 
III. Consensus models 
AZ Descriptors  
9 SVM(A,d)_RF(A,d)  
Consensus models based on the two ML algorithms, SVM and 
RF,  and the two modeling workflows (direct and indirect),  
with only AZ descriptors set 
10 SVM(A,i)_RF (A,i)  
11 SVM(A,d)_ SVM(A,i)  
12 RF(A,d)_ RF (A,i) 
13 SVM(A,d)_ RF (A,i) 
14 SVM(A,i)_RF(A,d)  
15 SVM(A,d)_SVM(A,i)_RF(A,d)  
16 SVM(A,d)_SVM(A,i)_RF(A,d) +RF(A,i)  
17 SVM(A,d) _RF(A,d)_RF(A,i)  
 Signature Descriptor   
18 SVM(S,d)_SVM(S,i) Consensus model based on only signature descriptors 
 AZ Descriptors & Signature Descriptor   
19 SVM(A,d)_RF(A,d)_SVM(S,d)  
Consensus models based on two different descriptors, model 
workflows and ML algorithms 
20 SVM(A,d)_RF(A,d)_SVM(S,i)  
21 SVM(A,d)_RF(A,d)_ SVM(S,d) _SVM(S,i)  
22 SVM(A,d)_RF(A,i)_RF(A,d)_SVM(S,d)  
23 SVM(A,d)_ SVM(A,i)_RF(A,i)_RF(A,d)_SVM(S,d)  
24 SVM(A,d)_SVM(A,i)_RF(A,i)_RF(A,d)_SVM(S,d)_SV
M(S,i)  
    
25 IV. Conformal prediction CP_SVM(S, i)  Conformal predictor on SVM Indirect model  built based on 
signature descriptors 
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2.5 Model Validation 
Validation is a vital step for building a good QSAR model as it shows the goodness of fit of 
the model under consideration. Two types of validations are commonly performed to assess 
the predictive powers of a QSAR model. 
Internal validation is used to determine the model fit, which gives an idea of how an unseen 
example might be handled by the model. Most commonly employed methods are leave one 
out cross –validation Q2, k-fold cross validation and so on. It is measured in terms of cross 
validated correlation coefficient or Q
2
. In the present work, k-fold cross validation was used 
during the model validation. 
External validation refers to the use of an external test set which is not included in the dataset 
used to build the model. The performance of the model on the test set is often measured in 
terms of the coefficient of determination, R
2 
and RMSE. 
R
2
 value denotes the correlation coefficient, which describes how good the predictions from 
the model are. A high R
2
 value is thus indicative of a good predictability of the model under 
consideration. In essence, R
2
 basically represents the percent of data that is closest to the best 
fit line, thus gives a picture of how well the data under consideration is explained by the 
regression equation set up. The value of R
2
 ranges from 0 to 1. An R
2
 of zero is attributable to 
a case where none of the variation in the observations can be explained by the variation in the 
independent variables whereas a value of 1 describes an ideal case of exact explanation 
[38]
. 
RMSE (Root mean square error) represents the extent by which the predicted values deviate 
from the true experimental values. It is calculated as the square root of mean squared error 
that evaluates the square of difference between the observed and the predicted values. 
   
    (5) 
Where Yobs is the observed value of the dependent variable and Ypred is predicted value of the 
dependent variable. 
2.1.6 Classification model  
Classification models were evaluated by categorizing the data into classes based on certain 
criteria. Classification criteria used in this study are as follows. 
Two-class classification: The prediction results from the model were classified based on a 
cut off at -1, where a logKp,uu,brain value greater than or equal to -1 renders the compound as 
BBB positive while values less than -1 implies BBB negative.  BBB positive implying the 
√ (Y
obs
-Y
pred
)
2
 
n 
RMSE = 
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ability of the compound to permeate the BBB while BBB negative implying inability of the 
compound to do so. 
Three-class classification: A three-class model was also built based on a cut off at two levels 
where a logKp,uu,brain>=-0.52 is defined as HIGH, logKp,uu,brain <-1.3 as LOW and all 
compounds between logKp,uu,brain - 1.3 and -0.52 as MODERATE. Here the compounds under 
the HIGH category are said to have a greater chance of permeating the BBB while those in 
LOW class have little chance.  
Throughout the analysis, the classification performance have been measured based on certain 
parameters. To calculate these parameters, a confusion matrix is first constructed. A 
confusion matrix is a matrix representing how well the prediction fits the actual values. This 
is analyzed based on the fraction of True Positives (TP), False Positives (FP), True Negatives 
(TN) and False Negatives (FN) in the predictions.  The primary measures used are as 
described in table 2.2.  
• Accuracy describes the fraction of correctly predicted instances.  
• Sensitivity or recall is proportion of positives that are correctly predicted as positive.  
• The fraction of negatives that are correctly predicted as negatives comprise the Specificity. 
• Negative Precision and Positive precision describe the accuracy of prediction of negative and 
positive class respectively. 
• F-score provides a measure of accuracy considering the harmonic average of recall and 
precision.     
• Kappa score measures the difference between the observed agreement and the agreement 
expected to be present just by chance. 
• Matthew’s coefficient represents the correlation between the observed and predicted binary 
classification. 
 
Table  2.2 Classification performance measures 
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2.6 Model Interpretation  
Further, an analysis of substructures and descriptors were performed for the training sets used 
to build the Kp,brain, Vu,brain and fu,p models. This gives an idea of the overall trend represented 
by the model. This was performed to analyze the dataset for potential indications of 
association of values of Kp,brain, Vu,brain and fu,p  with the substructures that they possess or the 
descriptors that are used to best describe them and to corroborate the data already known 
about the same.  
 
2.6.1 Signature descriptor gradient 
An in-house script was used to produce the SVM decision function gradient values for each 
of the training set predictions made by the individual models of Kp,brain, Vu,brain and fu,p. 
These were used to infer the substructure that can possibly have the most effect (positive or 
negative) on the values of Kp,brain, Vu,brain and fu,p  respectively. 
 
2.6.2 AZ descriptor gradient 
A similar analysis was performed with AZ descriptors using some in-house python scripts 
using modules from the in-house implementation of the Orange package. The gradient values 
were analyzed to evaluate the descriptors showing the highest positive or negative effects on 
the end point values. 
 
2.6.3 VIP values (Variable importance of projection) 
An in-house python script that calculates the VIP values based on random forest model was 
used to analyze the descriptor importance in each of the Kp,brain, Vu,brain and fu,p  models. The 
descriptors with the highest VIP values were analyzed to make specific inferences. 
Based on the calculated VIP values, the important descriptors were ranked in both models 
using RF with AZ descriptors and RF with signature descriptors. 
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3. RESULTS AND DISCUSSIONS 
 
3.1 Compounds in the dataset 
As mentioned earlier, some characteristics of compounds are favorable for a good 
distribution across the blood-brain barrier. An overview of the trend of these properties 
among the compounds in the dataset used is as shown in figure below. 
Figure 3.1a shows the trend of the Kp,uu,brain values in the dataset. The average value is around 
-1.09± 0.75 as indicated. It can be noticed that a large majority of the data points lie in the 
intermediate region.  
 
a. logKp,uu,brain 
 
b. ClogP 
 
c. Rotatable bonds 
 
d. Molecular weight 
 
e. Polar count 
 
f. Non-polar count 
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g. PSA 
 
h. Hydrogen bond acceptor 
 
 
 
 
 
 
 
 
i. Hydrogen bond donor 
 
 
j. Acids 
 
 
k. Bases 
 
 
l. Neutral 
Figure 3.3: Overview of the trend of some properties across the dataset. 
ClogP denotes lipophilicity of the compound, and is an important parameter for BBB 
penetration. Some studies have shown the mean ClogP for CNS drugs to be around 2.1
[24]
. 
The dataset used in the study shows an average ClogP value of around 2.55 ± 1.61(Figue1 
(b)) which seems to be close to that value. The molecular rigidity is often defined using 
number of rotatable bond; a potential CNS drug is thought to have a slightly higher rigidity 
than Non-CNS drugs. The dataset here consists of an average rotatable bond count of around 
~6.47 (Figure 1(c)). 
The dataset represents a set of compounds with a molecular weight average at approximately 
409±84 (Figure1 (d)), which seems good as for a CNS drug the range usually suggested is 
around 400-450. It is also known that CNS drugs have a higher non-polar count than their 
non-CNS counterparts, which is reflected in the figures 1(e) and 1(f).  
Hydrogen bonding properties are critical for CNS drugs, an overall picture of how HBA and 
HBD are distributed across the dataset is represented in Figure 1(h) and 1(i). The figures 1(j) 
1(k) and 1(l) represent the details of number of acids, bases and neutral compounds in the 
dataset. 
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3.2 Validation of the Current Kp,uu,brain model 
Upon the external validation of the model built in 2011 using test set consisting of 
compounds from the new dataset for which Kp,uu,brain data was available (100 compounds), it 
was seen that the model gave a correlation coefficient, R
2
 of 0.46 which increased to 0.53 on 
removal of a clear outlier(Figure 3.2a and b), while the RMSE decreased from 0.63 to 0.58. 
The original study in 2011 had seen a R
2
 value of 0.58 with an external test set. This was thus 
indicative of the stability of the performance of the current model.  
This outlier had a unusually high experimental value, which can be noticed in the distance of 
the point marked from the best fit line. 
 
a. 
 
R
2
 0.46 
RMSE 0.63 
Observations  100 
 
b. 
 
R
2
 0.53 
RMSE 0.58 
Observations  99 
Figure 3.4 Prediction results on the temporal test set. 
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Predicted Kp,uu,brain 
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3.2.1 Classification performance: 
Classification performance of the model was determined based on the two difference methods 
of categorization, namely, two-class classification and three-class classification. 
Two class classification:  
A two class classification on the prediction given by the current model on the temporal test 
set (with the outlier removed) is as shown (Table 3.1 and 3.2). For assessing the classification 
performance, firstly, a confusion matrix was constructed where the prediction was evaluated 
and categorized into true positives, false positives, true negatives and false negatives. 
Determining the performance measures showed that the prediction had a decent accuracy of 
around 76% with a good sensitivity and specificity of 74% and 77% respectively.  
Table 3.1 Confusion Matrix for two-class classification 
                    
 
TP  34  
FP  12  
TN  41  
FN  12  
Total  99  
Table 3.2 Performance Measures for two-class model 
 
 
 
 
 
 
Accuracy  0.76  
Sensitivity  0.74  
Specificity  0.77  
Positive Precision  0.74  
Negative Precision  0.77  
F-score  0.74  
Kappa  0.51  
Matthews correlation coefficient  0.51  
 
 
Figure 3.5 A chart representing a comparison between the experimental and 
predicted data of logKp,uu,brain. 
0%
20%
40%
60%
80%
100%
Predicted Positive Predicted negative
34 
12 
12 
41 Negative
Positive
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Three –class classification: 
From the various performance measures calculated from the confusion matrix, a classification 
accuracy of 92%, 81% and 40% for HIGH, LOW and MODERATE class respectively (table 
3.3), was observed. These results were again in line with what was observed in the previous 
study in 2011. 
It is important to note that about 57% of the compounds belong to the Moderate class (table 
3.3 and figure 3.4). The low prediction accuracy for the moderate class largely deteriorates 
the accuracy of the three class model for the whole dataset. 
Table 3.3 Confusion matrix for High, Low and Moderate classes 
 
 
 
HIGH  LOW  MODERATE 
TP 11 TP 25 TP 23 
FP 1 FP 5 FP 34 
Precision 0.92 Precision 0.833 Precision 0.40 
 
 
 
Figure 3.6 Comparison of predicted results with the experimental values using a three-class 
model 
 
Overall, these observations give us a good confidence in the predictive powers of the current 
model. On the other hand, it is important to realize that it is necessary to update these in-
silico models with temporal datasets to further extend the chemical space represented by the 
training set, thus further improving the chances of a good prediction of unknown compounds.  
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3.3 Signature SVM model built on the old dataset  
After the validation of the current model, an attempt was made to check the performance of 
the model built using signature molecular descriptors. This model was built based on the old 
dataset (used in the 2011 study) to evaluate the performance using signature molecular 
descriptor as the study in 2011 used only the AZ descriptors set. The specifications of the 
model are as listed in the table below (table 3.4). 
 
Table 3.4 Model specifications  
Model type Direct and Indirect model 
Machine learning algorithm SVM 
Descriptor Signature molecular descriptors 
Size of dataset (Training set) (Direct model) 
 
 
Kp,uu,brain     : 173 
Kp,brain   : 432 
Vu,brain  : 399 
fu,p   : 3161 
Size of dataset (Test set)  74  
 
External validation of the model gave an R
2
 of 0.52 and RMSE of 0.50 for the direct model 
and R
2
 of 0.46 and RMSE of 0.59 for indirect model (Figure 3.5 and 3.6). This was observed 
to be similar to the results that were obtained using the set in-house physico-chemical 
descriptors in the 2011 study (Direct Model R
2
 of 0.53 and RMSE of 0.48 and Indirect Model 
R
2
 of 0.42 and RMSE of 0.54) 
 
From this study it could be inferred that signature molecular descriptor alone does not greatly 
improve the performance of this particular model. Further the descriptor was employed in the 
model building along with the AZ descriptors to determine if consensus between the AZ 
descriptor and the signature descriptor can further improve the model. 
At this stage, different signature height ranges were checked for any improvement of the 
model. Since there was no significant improvement, a signature height range of 0-3 was used 
throughout the study. 
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Figure 3.7 Direct Model: Predicted vs Experimental  Values 
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Figure 3.8 Indirect Model: Predicted vs Experimental Values 
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Predicted Kp,uu,brain 
Indirect Model (Signature+SVM) 
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The subsequent studies aimed at building a Model with the inclusion of the new data in the 
original dataset. The outlier (represented in Figure 3.2) was removed from the dataset. It was 
then attempted to improve the performance of the model using a different approach to model 
building.  
3.4 Single component models  
The subsequent studies involved model building using the dataset where the new and the old 
data (until 2011) were combined. During the model building, the whole dataset was randomly 
split into training and test set with the ratio of 7:3 and random splitting was repeated 10 times 
and thus 10 models were built of each model type. 
Table 3.6 lists and explains the notations used to represent the models, throughout the report.  
 
Table 3.5 : Model specifications  
Model type Direct model and Indirect 
Machine learning algorithm SVM and RF 
Descriptor AZ Descriptor and Signature descriptor 
Size of dataset (Training set) (Direct model) 
 
 
Kp,uu,brain     : 242 
Kp,brain   : 617 
Vu,brain  : 1105 
fu,p   : 5651 
Size of dataset (Test set)  104  
 
Table 3.6 Notations for the single component models. 
Model  ML 
Algorithm 
Model workflow Descriptor 
SVM_(A, d) SVM Direct AZ Descriptors 
RF_(A, d) RF Direct AZ Descriptors 
SVM_(S, d) SVM Direct Signature descriptor 
SVM_(A, I) SVM Indirect AZ Descriptors 
RF_(A, I) RF Indirect AZ Descriptors 
SVM_(S, I) SVM Indirect Signature descriptor 
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3.4.1 Internal Validation 
For the models using AZ descriptor, the internal cross validation q
2
 was calculated for all the 
datasets. The Average cross validation R
2 
(q
2
) for direct model was found to be 0.63 with 
SVM and 0.64 with RF respectively  (Figure 3.7) and in case of indirect model, Kp,brain, 
Vu,brain and fu,p had an average of 0.67, 0.67 and 0.80 respectively  with SVM and 0.70 ,0.65 
and 0.78 with RF (Figures 3.8, 3.9, 3.10).  The range of R
2 
values obtained with the internal 
validation is indicative of the good internal predictive performance of the models. 
The graphs represent the trend of the variation in cross-validation R
2
 (q
2
) for the direct model 
and the 3 component models of the indirect model. The x-axis represents the models and y-
axis represents the R
2
 values. 
 
 
 
Figure 3.9 Graph representing the q2 of the 10 training sets (Direct Model). 
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Figure 3. 10 Graph representing the q
2 
values of Kp,brain 
model across the 10 sets of data. 
 
ML 
Algorithm 
SVM RF 
R
2
 0.55 0.52 
RMSE 0.53 0.53 
 
Figure 3.11 Graph representing the q
2
 values of Vu,brain model 
across the 10 sets of data 
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Figure 3.12 Graph representing the q
2
 values of fu,p model 
across the 10 sets of data 
 
ML 
Algorithm 
SVM RF 
R
2
 0.81 0.78 
RMSE 0.38 0.4 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
1 2 3 4 5 6 7 8 9 10
R
2 
Model 
Kp,brain model 
SVM_Kp,brain
RF_Kp,brain
0.68
0.7
0.72
0.74
0.76
0.78
0.8
0.82
1 2 3 4 5 6 7 8 9 10
R
2
 
Model 
Vu,brain model 
SVM_Vu,brai
n
RF_Vu,brain
0.765
0.77
0.775
0.78
0.785
0.79
0.795
0.8
0.805
0.81
0.815
1 2 3 4 5 6 7 8 9 10
R
2 
Model 
fu,p Model 
SVM_fu,p
RF_fu,p
 35 
 
3.4.2 External validation of the Kp,uu,brain models 
External validation involved testing the 104 compounds of the test set on the model built. The 
predictions on the test sets from the six single component models gave an insight into the 
machine learning method and the descriptors that are providing the best predictions for each 
of the dataset. Among the models built, it was seen that the indirect models based on SVM 
and RF with the in-house physicochemical descriptors gave the best predictions with an 
average R
2
 of 0.59 and an average RMSE of 0.49 in both cases. But, the model based on RF 
was considered to be the best among the two, owing to the more consistent predictions as 
seen in the graph (Figure 3.11). This was inferred based on the average R
2
 over the 
predictions of all the 10 models in each case (Table 3.7).  
 
Figure 3.13  R
2
 across the ten datasets for each of the models. 
 
Table 3.7  Performance of the models (Average over 10 sets) 
Model R
2
 RMSE 
SVM_(A, d)  0.57  0.49  
RF_(A, d)  0.54  0.52  
SVM_(S, d)  0.51  0.53  
SVM_(A, I)  0.59  0.49  
RF_(A, I)  0.59  0.49  
SVM_(S, I)  0.5  0.57  
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Some regression curves for the six single component models as explained above are 
represented with the equation and respective R
2
 values (Figure 3.12). In the regression 
graphs, the x-axis represents the Kp,uu,brain prediction values and y-axis represents the 
experimental or observed values. The line represented in the graphs is called the best fit line 
which basically best describes the data on the scatter plot.  
 
 
  
  
Figure 3.14 Regression curves for the six single component models of one of the datasets 
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3.5 Consensus Models: 
Following the analysis of the single component models, consensus models were built by 
taking the average of the predictions from the individual components. Various combinations 
of the descriptors, the machine learning algorithms and modeling schemes (direct and 
indirect) were tried out (Table 3.8). 
As it can be observed from the R
2
 values, consensus model seem to perform better as 
compared to their single component counterparts. Most of the models gave an R
2
 of above 
0.6. The consensus model based on only signature descriptor seemed to perform slightly 
poorer compared to the ones with AZ Descriptors. 
Based on the R
2
 and RMSE values the best four consensus models were picked for further 
analysis (Figure 3.13) 
 
Table 3.8: Consensus models 
Model  R
2
  RMSE  
AZ Descriptor  
SVM(A,d)_RF(A,d)  0.60  0.48  
SVM(A,i)_RF (A,i)  0.63  0.46  
SVM(A,d)_ SVM(A,i)  0.62 0.46  
RF(A,d)_ RF (A,i) 0.60  0.48  
SVM(A,d)_ RF (A,i) 0.63 0.46  
SVM(A,i)_RF(A,d)  0.62  0.47  
SVM(A,d)_SVM(A,i)_RF(A,d)  0.63 0.46  
SVM(A,d)_SVM(A,i)_RF(A,d) +RF(A,i)  0.63  0.47  
SVM(A,d) + RF(A,d) + RF(A,i)  0.64 0.46  
Signature Descriptor  
SVM(S,d)_SVM(S,i)  0.56 0.51  
AZ Descriptors & Signature Descriptor  
SVM(A,d)_RF(A,d)_SVM(S,d)  0.61 0.48  
SVM(A,d)_RF(A,d)_SVM(S,i)  0.62  0.46  
SVM(A,d)_RF(A,d)_ SVM(S,d) _SVM(S,i)  0.62 0.47  
SVM(A,d)_RF(A,i)_RF(A,d)_SVM(S,d)  0.63  0.46  
SVM(A,d)_ SVM(A,i)_RF(A,i)_RF(A,d)_SVM(S,d)  0.65  0.45  
SVM(A,d)_SVM(A,i)_RF(A,i)_RF(A,d)_SVM(S,d)_SVM(S,i)  0.65 0.45  
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Figure 3.15 Graph showing the variation of R
2
 values across the ten sets. 
 
Further, classification performance was checked for the top four consensus models that 
showed the best performance. 
Classification models using the best consensus models involved classifying the prediction of 
the model based on the 2-class (logKp,uu,brain >= -1 as positive and logKp,uu,brain < -1 as 
negative) or 3- class ( logKp,uu,brain  >= -0.52 (HIGH), logKp,uu,brain  < -1.3 as (LOW), -0.52 < 
logKp,uu,brain  >= -1.3 as (MODERATE)) categories. In general, different approaches exist to 
derive consensus models. In the current study, different approaches for calculations of 
consensus prediction were attempted by using Average, median, maximum value (where the 
maximum value among the predictions from the different model is taken as the consensus 
prediction) and minimum value (where the minimum value among the predictions from the 
different model is taken as the consensus prediction).  
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
1 2 3 4 5 6 7 8 9 10
R
2 
Models 
Consensus Models 
RF(A,i)
SVM(A,d)_RF(A,d)_RF(A,i)
SVM(A,d)_RF(A,i)_RF(A,d)_SV
M(S,d)
SVM(A,d)_
SVM(A,i)_RF(A,i)_RF(A,d)_SV
M(S,d)
SVM(A,d)_SVM(A,i)_RF(A,i)_R
F(A,d)_SVM(S,d)_SVM(S,i)
 39 
 
3.5.1 Two class classification  
Table 3.9 Classification performance (Two Class)  of the best consensus models using different ways of data fusion ( Average, Median, Max Value and Min Value) 
 
 Accuracy Sensitivity Specificity Positive 
precision 
Negative 
precision 
F-
score 
Kapp
a 
Matthews 
Coefficient 
AVERAGE 
SVM(A,d) _RF(A,d)_RF(A,i) 0.836 0.802 0.858 0.799 0.861 0.8 0.66 0.659 
SVM(A,d)_RF(A,i)_RF(A,d)_SVM(S,d) 0.836 0.814 0.848 0.791 0.867 0.8 0.662 0.66 
SVM(A,d)_ SVM(A,i)_RF(A,i)_RF(A,d)_SVM(S,d) 0.843 0.823 0.852 0.8 0.874 0.809 0.677 0.675 
SVM(A,d)_SVM(A,i)_RF(A,i)_RF(A,d)_SVM(S,d)_S
VM(S,i) 0.839 0.817 0.849 0.796 0.869 0.804 0.668 0.666 
MEDIAN 
SVM(A,d) _RF(A,d)_RF(A,i) 0.835 0.789 0.863 0.803 0.855 0.795 0.658 0.655 
SVM(A,d)_RF(A,i)_RF(A,d)_SVM(S,d) 0.831 0.805 0.847 0.785 0.861 0.792 0.651 0.65 
SVM(A,d)_ SVM(A,i)_RF(A,i)_RF(A,d)_SVM(S,d) 0.837 0.813 0.846 0.793 0.868 0.8 0.664 0.661 
SVM(A,d)_SVM(A,i)_RF(A,i)_RF(A,d)_SVM(S,d)_S
VM(S,i) 0.839 0.818 0.848 0.795 0.871 0.804 0.669 0.666 
MAXIMUM 
SVM(A,d) _RF(A,d)_RF(A,i) 0.799 0.89 0.729 0.7 0.905 0.782 0.6 0.612 
SVM(A,d)_RF(A,i)_RF(A,d)_SVM(S,d) 0.78 0.918 0.678 0.67 0.921 0.774 0.57 0.592 
SVM(A,d)_ SVM(A,i)_RF(A,i)_RF(A,d)_SVM(S,d) 0.762 0.949 0.628 0.646 0.948 0.766 0.541 0.585 
SVM(A,d)_SVM(A,i)_RF(A,i)_RF(A,d)_SVM(S,d)_S
VM(S,i) 0.75 0.968 0.597 0.631 0.966 0.762 0.523 0.58 
MINIMUM 
SVM(A,d) _RF(A,d)_RF(A,i) 0.825 0.654 0.941 0.885 0.795 0.749 0.621 0.638 
SVM(A,d)_RF(A,i)_RF(A,d)_SVM(S,d) 0.816 0.607 0.96 0.917 0.775 0.729 0.6 0.624 
SVM(A,d)_ SVM(A,i)_RF(A,i)_RF(A,d)_SVM(S,d) 0.816 0.589 0.971 0.933 0.771 0.721 0.599 0.628 
SVM(A,d)_SVM(A,i)_RF(A,i)_RF(A,d)_SVM(S,d)_S
VM(S,i) 0.806 0.565 0.972 0.935 0.76 0.702 0.574 0.609 
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From the 2-class classification performance measures it can be seen that consensus prediction 
based on minimum value has lower sensitivity and higher specificity while the one with the 
maximum value has a lower specificity and higher sensitivity (Table 3.9). Thus, as it can be 
noted, among the different methods, average calculation seemed to give a more consistent 
result. On an average, the models showed an accuracy of around 0.84 with a sensitivity or 
recall of approximately 0.81 and specificity of around 0.85. A Kappa value of around 0.67 on 
shows a good predictive performance of these models.  
 
3.5.2 Three class Classification   
Similar to the trend noticed with the 2-class classification results, the average method of 
calculating consensus prediction for 3-class model seemed to be more consistent across the 
models (table 3.10) . The precision fell in the range of 81-86%, 81-82% and 46-50% for the 
HIGH, LOW and MODERATE classes respectively. 
Table 3.10 Classification performance (three-class) of the best consensus models using different 
ways of data fusion (Average, Median, Max Value and Min Value) 
 Precision 
HIGH 
Precision  
LOW 
Precision 
MODERATE 
AVERAGE 
SVM(A,d) _RF(A,d)_RF(A,i) 0.816 0.806 0.456 
SVM(A,d)_RF(A,i)_RF(A,d)_SVM(S,d) 0.808 0.808 0.459 
SVM(A,d)_ SVM(A,i)_RF(A,i)_RF(A,d)_SVM(S,d) 0.862 0.819 0.479 
SVM(A,d)_SVM(A,i)_RF(A,i)_RF(A,d)_SVM(S,d)_SVM(S,i) 0.81 0.828 0.491 
MEDIAN 
SVM(A,d) _RF(A,d)_RF(A,i) 0.815 0.806 0.454 
SVM(A,d)_RF(A,i)_RF(A,d)_SVM(S,d) 0.834 0.801 0.457 
SVM(A,d)_ SVM(A,i)_RF(A,i)_RF(A,d)_SVM(S,d) 0.85 0.817 0.479 
SVM(A,d)_SVM(A,i)_RF(A,i)_RF(A,d)_SVM(S,d)_SVM(S,i) 0.826 0.817 0.492 
MAXIMUM 
SVM(A,d) _RF(A,d)_RF(A,i) 0.674 0.874 0.438 
SVM(A,d)_RF(A,i)_RF(A,d)_SVM(S,d) 0.645 0.889 0.419 
SVM(A,d)_ SVM(A,i)_RF(A,i)_RF(A,d)_SVM(S,d) 0.653 0.885 0.397 
SVM(A,d)_SVM(A,i)_RF(A,i)_RF(A,d)_SVM(S,d)_SVM(S,i) 0.619 0.892 0.375 
MINIMUM 
SVM(A,d) _RF(A,d)_RF(A,i) 0.89 0.744 0.431 
SVM(A,d)_RF(A,i)_RF(A,d)_SVM(S,d) 0.907 0.714 0.424 
SVM(A,d)_ SVM(A,i)_RF(A,i)_RF(A,d)_SVM(S,d) 0.909 0.719 0.404 
SVM(A,d)_SVM(A,i)_RF(A,i)_RF(A,d)_SVM(S,d)_SVM(S,i) 0.915 0.701 0.4 
 
From all the results described above, it can be noted that the best performance is exhibited by 
the 5-component model: SVM(A,d)_SVM(A,i)_RF(A,i)_RF(A,d)_SVM(S,d). This model 
has an average R
2
 of 0.65 with RMSE of 0.45, average two-class classification accuracy of 
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84% and an average precision of 48% for predicting Moderate class in the 3-class 
classification. Here we can see a clear improvement in the performance as compared to the 
validation result. The figures below (Figure 3.14,3.15 and 3.16) summarize sample results 
from one of the 10 SVM(A,d)_ SVM(A,i)_RF(A,i)_RF(A,d)_SVM(S,d) models. 
 
Figure 3.16 Sample regression plot for the 5 component consensus model (one of the 10 runs). 
 
  
Figure 3.17 (a) Two-class classification and (b) confusion matrix for the 5-component model 
(one of the 10 runs) 
 
 
Figure 3.18: Three-class classification for the 5 component consensus model (one of the 10 runs) 
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3.6 Conformal Prediction 
An indirect conformal prediction model was built using the dataset corresponding to the best 
model among the 10 runs used in section 3.5. The model utilized signature molecular 
descriptors. The purpose of using conformal predictors is to be able to associate the 
predictions from the model to a confidence score.  
In this case, the error percentage and interval length at every confidence level was computed 
for each of Kp,brain, Vu,brain and fu,p. Kp,uu,brain interval was calculated by combining the 
minimum and maximum values of each of the components. The table below (table 3.11) 
shows the specifications of the model and the dataset used. 
 
Table 3.11 Model specifications  (Conformal predictor) 
Model type SVM Signature -> Conformal predictor  
( Indirect Model ) 
Machine learning algorithm SVM 
Descriptor Signature descriptor 
Size of dataset (Training set)  
 
 
Kp,brain   : 617 
Vu,brain  : 1105 
fu,p   : 5651 
Size of dataset (Test set)  104  
 
To make useful inferences of the intervals obtained from the conformal predictor, 
experimental ranges of Kp,brain, Vu,brain and fu,p  were analyzed as summarized in table below 
(Table 3.12).  
Range of Experimental Values: 
Table 3.12  Experimental values range for the various parameter. 
logKp,brain - 2.46 to 1.33 
logVu,brain -0.24 to 3.52 
logfu,p -1.98 to 2.00 
logKp,uu,brain  -2.46 - 0.68 
 
The Kp,brain, Vu,brain and  fu,p component models (Tables 3.13, 3.14 and 3.15) were built and the 
predictions from these were used to calculate Kp,uu,brain. The models showed a consistency 
between the RMSE and the interval lengths. 
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Table 3.13 Prediction from Kp,brain model. 
Confidence 
Levels 
%Error  in the 
prediction 
Average Interval 
Length 
Average coefficient of 
variation 
40 61.54 0.87 1.14 
45 58.65 0.99 1.29 
50 53.85 1.11 1.44 
55 47.12 1.27 1.66 
60 37.50 1.50 1.95 
65 34.62 1.65 2.14 
70 32.69 1.87 2.43 
75 31.73 2.01 2.61 
80 21.15 2.68 3.48 
85 16.35 3.06 3.97 
90 6.73 3.83 4.97 
95 2.88 4.93 6.40 
 
Model Prediction 
R
2
 RMSE 
0.57 0.53 
 
 
Table 3.14  Prediction from Vu,brain model 
Confidence 
levels 
%Error  in the 
prediction 
Average Interval 
Length 
Average coefficient of 
variation 
40 68.27 0.19 0.16 
45 60.58 0.26 0.21 
50 57.69 0.30 0.24 
55 54.81 0.33 0.27 
60 51.92 0.37 0.30 
65 44.23 0.49 0.40 
70 42.31 0.55 0.45 
75 35.58 0.62 0.50 
80 26.92 0.76 0.61 
85 20.19 0.99 0.80 
90 11.54 1.24 1.00 
95 4.81 1.80 1.45 
 
Model Prediction  
R
2
 RMSE 
0.75 0.36 
 44 
 
 
 
 
Table 3.15 Prediction from fu,p model 
Confidence 
levels 
%Error  in the 
prediction 
Average Interval 
Length 
Average coefficient of 
variation 
40 68.27 0.19 0.17 
45 64.42 0.24 0.21 
50 53.85 0.32 0.29 
55 44.23 0.39 0.35 
60 41.35 0.46 0.42 
65 34.62 0.53 0.48 
70 30.77 0.58 0.52 
75 23.08 0.77 0.69 
80 18.27 0.88 0.79 
85 14.42 1.10 0.99 
90 9.62 1.52 1.37 
95 7.69 1.69 1.53 
 
Model Prediction 
R
2
 RMSE 
0.76 0.36 
 
Kp,uu,brain Calculations: 
For calculating Kp,uu,brain value range the formula the formula as given in the table (3.16) 
below was used. This formula is based on the Equation (3).   
Table 3.16  Equation used to calculate Kp,uu,brain ranges. 
Maximum logKp,uu,brain = MaxlogKp,brain –MinlogVu,brain-Minlogfu,p +2 
Minimum logKp,uu,brain = MinlogKp,brain –MaxlogVu,brain-Maxlogfu,p +2 
 
From Table 3.17, it can be noted that the conservative validity of the conformal prediction is 
not satisfied as the error rates at each confidence level do not correspond to the ϵ and 1-ϵ 
relationship (5% error at 95% confidence). This can probably be overcome with a different 
approach to calculation of the Kp,uu,brain interval.  The interval length increases from 1.26 (at 
40% confidence) to 8.42 (at 95% confidence) these high interval lengths make the 
interpretation of the results somewhat complex. However, the model performance in terms of 
the RMSE seems to be consistent with the interval length (low RMSE).  
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Table 3.17 Prediction from Kp,uu,brain indirect model 
Confidence 
levels 
%Error  in the 
prediction  
Average Interval 
Length  
Average coefficient of 
variation 
40 47.12 1.26 0.17 
45 41.35 1.49 0.21 
50 33.65 1.73 0.29 
55 27.88 2.00 0.35 
60 18.27 2.33 0.42 
65 13.46 2.67 0.48 
70 9.62 3.00 0.52 
75 6.73 3.39 0.69 
80 3.85  4.32 0.79 
85 1.92 5.15 0.99 
90 0 6.58 1.37 
95 0 8.42 1.53 
 
Model Prediction  
R2 RMSE 
0.48  0.58  
 
 
As described by the Three Sigma rule (or 68-95-99.7 rule), for a normally distributed dataset, 
±1 standard deviation interval of the mean is where ~68% of the data points lie.  
Thus checking for the average for experimental values of Kp,brain, Vu,brain and fu,p and 
doubling the value we get the interval length where 60% of the data points are to lie, 
assuming that the data is normally distributes (Table 3.18). 
To understand the interval length given by the conformal prediction, experimental interval 
length was determined as above and compared to the interval lengths in case of confidence 
levels of 60%, 65% and 70% (Table 3.19). 
 
Table 3.18 Comparison of the standard deviation and interval length. 
 Avg Standard deviation Interval Length 
Kp,brain 0.1069 0.2138 
Vu,brain 0.2208 0.4416 
fu,p 0.1008 0.2016 
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Table 3.19 Comparison of the interval lengths at the confidence levels of 60, 65 and 70%. 
 Interval Length 
 60 65 70 
Kp,brain 1.5 1.65 1.87 
Vu,brain 0.37 0.49 0.55 
fu,p 0.46 0.53 0.58 
 
It can be noted from the above results that the interval length obtained Kp,brain and fu,p are 
much higher than the experimental interval lengths thus making it difficult to give accurate 
predictions with high confidence, while the interval length in case of Vu,brain seems to be 
slightly better (which is again consistent with the better model performance as shown by the 
R
2
 and RMSE values). 
Conformal prediction probably points to the inherent noise in the experimental measurement 
data due to which the IID (Independent and identically distributed) assumption may not be 
satisfied.  
However, in all cases shown above, the conformal prediction results were consistent in 
comparison to the model performance as observed from the R
2
 and RMSE values. 
3.7 Kp,brain Modeling approach  
This model was an approach to understand if improving the Kp,brain component alone can 
improve the Kp,uu,brain prediction of the model while utilizing experimental data for Vu,brain and 
fu,p. 
Among the various Kp,brain consensus models, the model with all the 3 component models ( 
SVM+AzDesc, RF+AZDesc and SVM+Signature descriptors)  gave the best performance 
with an R
2
 of 0.72 and a RMSE of 0.47. This model was used to build a kind of indirect 
model where the Kp,brain consensus model was used along with the experimental Vu,brain and 
fu,p to calculate Kp,uu,brain. Values obtained from such a calculation are as represented in the 
table below (Table 3.20). Average over all the ten models gave an R
2
 of 0.64 and RMSE of 
0.45. 
 Comparing these results to the values previously obtained from the consensus models, it can 
be seen that this model has a performance comparable to the performance of the best 
consensus models. 
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Table 3.20 Model Performance 
Dataset R
2
 RMSE 
1  0.68  0.41  
2 0.62  0.49  
3 0.64  0.46  
4 0.62  0.48  
5 0.67  0.48  
6 0.6  0.48  
7 0.61  0.43  
8 0.54  0.46  
9 0.67  0.43  
10 0.72  0.4  
Average 0.64  0.45  
For these models, classification performance was also evaluated and averaged over the 10 
runs (Table 3.21). Two-class classification gave an accuracy of around 84%, while with 3 
class, a precision of 81.4%, 82.3% and 51.3 % was obtained for HIGH, LOW and MEDIUM 
class respectively (Table 3.22). However, it can be noted that the precision for moderate class 
is somewhat higher than the previous models. 
Table 3.21 Two class classification performance. 
Two-class classification 
Accuracy   0.839 
Sensitivity  0.791 
Specificity  0.867 
Positive Precision  0.809 
Negative Precision  0.856 
F-score  0.8 
Kappa  0.666 
Matthews correlation coefficient  0.662 
 
Table 3.22 Three class classification performance 
Three-class classification 
Precision HIGH  0.814 
Precision LOW  0.823 
Precision MODERATE  0.513 
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3.9 Kp,uu,brain Model Interpretation 
3.9.1 Random Forest VIP values 
The table below summarizes the analysis of the descriptors based on RF VIP values (Table 
3.23). 
Among the top 15 descriptors for Kp,uu,brain most of them were related to polarity and 
molecular topology. These properties have been previously shown to be important 
determinants of Kp,uu,brain . However, it is also noticed that lipophilicity, though a very 
important factor for total brain-plasma concentration ratio (Kp,brain), does not appear in the list 
of top influential descriptors based on RF VIP values (ClogP). This is due to the fact that 
higher lipophilicity will lead to higher non-specific brain tissue and plasma protein binding 
and in the end has little influence on the Kp,uu,brain. 
Table 3.23 Top 15 descriptors based on RF VIP. 
Descriptor VIP  
MM_SAS_EP_P_SUM  0.023  
Sum of positive electrostatic potentials on solvent accessible 
surface.  
HBAsum  0.021  Sum of acceptor free energies according to Raevsky (HYBOT).  
Kappa2  0.021  Topological index.  
VDW_AREA  0.016  Van der Waals molecular surface area.  
MM_SAS_EP_P_MEAN  0.016  
Mean of positive electrostatic potentials on solvent accessible 
surface.  
MM_VDW_EP_P_SUM  0.015  
Sum of positive electrostatic potentials on Van der Waals 
surface.  
Kappa1  0.014  Topological index.  
CMR  0.014  
Calculated molar refractivity. Largely a volume descriptor, 
highly correlated with molecular weight.  
HBAmax  0.012  
Highest free energy factor for H-bond acceptors according to 
Raevsky (HYBOT).  
OVAL_NEW  0.012  TSA / the area of a sphere with the volume given by MolVol2D  
HBD  0.012  Lipinski number of HB donors = number of OH+NH.  
MM_VDW_EP_P_AREA  0.012  
Area of Van der Waals surface with positive electrostatic 
potential.  
AREA  0.012  
Van der Waals radius surface, summed over all atoms, with a 1-3 
overlap correction.  
Chi3p  0.011  
Sum of reciprocal square roots of valences over all 4-count linear 
atom paths.  
VOL  0.011  Gaussian volume. A measure of molecular volume.  
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3.9.2 AZ descriptor gradient values  
The most Influential AZ descriptors were also determined using the AZ Descriptor model 
with SVM. This was determined based on SVM decision function values. Based on the 
average decision function gradient values, a list of descriptors that potentially influence 
Kp,uu,brain  positively (Table 3.24) and negatively (Table 3.25) was highlighted. Based on the 
standard deviation within the gradient values, the descriptors that are not very influential in 
spite of having high average gradient values were removed from the list ( Standard deviation 
> absolute value of the average gradient values).   
This calculation performed on Kp,uu,brain data produced results that are very complex to 
interpret.   
Table  3.24 Top 15 positively influential descriptors based  on SVM decision function gradient 
Descriptor  Average  
Gradient 
 value  
Standard 
deviation  
Median  Description  
MM_HASA 4.168 2.554 3.737 A measure of the dispersion of the charge on 
hydrogen bond acceptor atoms on the surface. 
PolarCountMW  1.783 1.383 1.693 Polar count divided by molecular weight 
MM_HADSA 1.024 0.852 0.916 A measure of the dispersion of the charge on 
hydrogen bond donor and acceptor atoms on the 
surface. 
MM_QnegVar  0.938 0.853 0.862 Variance of negative charges . 
NonpolarCountMW  0.861 0.524 0.913 Nonpolar count divided by molecular weight 
MaxNegChargeGM  0.644 0.582 0.560 Maximum negative charge using the Gasteiger-
Marsili partial charge equilibration. 
AverNegCharge_GM  0.510 0.368 0.469 Average negative charge using the Gasteiger-
Marsili partial charge equilibration. 
MM_QposMean  0.264 0.166 0.271 Mean of positive charges. 
SPEC_SAS_NONPOL_ARE
A 
0.202 0.131 0.192 SAS_NONPOL_AREA / SAS_TOT_AREA. 
SIC 0.196 0.139 0.204 Structural information content of 0 order.  
SPEC_HB_TOT 0.187 0.117 0.175 HBsum/HeavyAtomCount. 
SPEC_VDW_HB_A_AREA 0.173 0.117 0.180 VDW_HB_A_AREA / VDW_AREA. 
MM_HACA 0.163 0.106 0.152 A measure of the dispersion of the charge on 
hydrogen bond acceptor atoms on the surface.) 
FractionNeutral  0.116 0.112 0.091 10 ^ (ACDlogD74 - ACDlogP) 
AverNegCharge_GH 0.106 0.081 0.076 Average negative charge using the Gasteiger-
Huckel partial charge equilibration. 
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Since Kp,uu,brain is a parameter involving many complex processes, interpretation of these 
descriptor is complex. 
Further work has to be carried out to be able to get a fundamental understanding of the listed 
influential descriptors.  
Table 3.25 Top 15 Negatively influential descriptors based  on SVM decision function gradient 
Descriptor  
Average  
Gradient 
 value  
Standard 
deviation  
Median  
Description  
MM_HDSA -4.572 3.677 -4.992 
A measure of the dispersion of the charge 
on hydrogen bond donor atoms on the 
surface. 
MM_QnegMean  -0.636 0.323 -0.659 Mean of negative charges. 
SPEC_SAS_HB_D_AREA -0.568 0.213 -0.557 SAS_HB_D_AREA / SAS_TOT_AREA. 
SPEC_VDW_HB_D_AREA -0.364 0.196 -0.373 VDW_HB_D_AREA / VDW_AREA. 
SPEC_FLEX_BND -0.276 0.110 -0.286 Defined as ratio FLEX_BND/HEAVIES. 
MM_HDCA -0.274 0.174 -0.293 
A measure of the dispersion of the charge 
on hydrogen bond donor atoms on the 
surface. 
SPEC_SAS_POL_AREA -0.202 0.131 -0.192 SAS_POL_AREA / SAS_TOT_AREA. 
OVAL_NEW -0.155 0.094 -0.122 
TSA / the area of a sphere with the volume 
given by MolVol2D 
FractionIonized -0.116 0.112 -0.091 (1 - FractionNeutral) 
MinEV3 -0.109 0.068 -0.098 
3rd smallest minimum eigenvalue from 
connectivity matrix, where diagonal has 
atomic weights. 
SPEC_VDW_POL_AREA -0.100 0.080 -0.094 VDW_POL_AREA / VDW_AREA 
HBAmax -0.070 0.045 -0.076 
Highest free energy factor for H-bond 
acceptors according to Raevsky (HYBOT). 
LUMO -0.063 0.045 -0.059 
Huckel molecular orbitals, Lowest 
unoccupied molecular orbital energy. 
Balaban -0.059 0.055 -0.034 
Topological distance matrix based index 
related to ring structures. 
MaxEV2 -0.014 0.008 -0.015 
2nd largest maximum eigenvalue from 
connectivity matrix, where diagonal has 
atomic weights. 
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3.9.3 Signature gradient values 
Decision function Gradient values were generated by a script that calculates the signature 
descriptors and builds an SVM model. These values somewhat represent the effect of the 
particular signature on the end point value. Thus this can be used to identify substructures 
within the molecule that could potentially exert a positive or negative effect.   
Based on the average gradient values, and analysis of other statistical parameters like 
standard deviation a set of top signatures have been selected and represented in the tables 
below (Tables 3.26 and 3.27). 
Complexity of the parameter Kp,uu,brain is reflected in the absence of an exact trend in the 
substructures obtained with signatures as with other methods (Figures 3.17 and 3.18). This 
necessitates a detailed study of the substructures obtained to possibly find any solid 
correlations with Kp,uu,brain. 
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Table 3.26 Top positively influential signatures for Kp,uu,brain 
Signature  Number  
of  
Occurences  
Average  
gradient  
values  
Standard  
deviation 
(of  
gradient 
 values)  
Classification  
(3- class)  
Average  
Experimental  
Value  
Standard  
Deviation 
(of 
Experimen
tal values)  
[C](p[C](p[C])p[C]([C]p[C]))  147  0.0641  0.0095 (L=66,H=33,M=48
)  
-1.12  0.75  
[N](p[C]p[C])  103  0.0509  0.0093 (L=38,H=28,M=37
)  
-1.02  0.78  
[C](p[C](p[C])p[C](p[C][F]))  33  0.0427  0.0101 (L=12,H=11,M=10
)  
-0.96  0.81  
[C]([C]p[C]p[C])  175  0.0424  0.0071 (L=76,H=42,M=57
)  
-1.09  0.75  
[C](p[C]([C]p[C])p[C](p[C][C]))  30  0.0411  0.0037 (L=12,H=4,M=14)  -1.20  0.55  
[C]([C](p[C]p[N]))  23  0.0325  0.0034 (L=6,H=12,M=5)  -0.52  0.84  
[C](p[C][N]p[N])  16  0.0323  0.0033 (L=2,H=10,M=4)  -0.45  0.77  
[C](p[C](p[C])p[C](p[C])[C](p[C]p[C]))  23  0.0321  0.0038 (L=0,H=13,M=10)  -0.25  0.50  
[C]([C]([C])[C]([C])[C]([C]))  13  0.0312  0.0038 (L=3,H=5,M=5)  -0.76  0.63  
[F]([C](p[C](p[C])p[C](p[C])))  21  0.0309  0.0087 (L=8,H=7,M=6)  -0.99  0.81  
[C](p[C](p[C])p[C](p[C])[F])  21  0.0309  0.0087 (L=8,H=7,M=6)  -0.99  0.81  
[C](p[C](p[C])p[C](p[C])[C]([N]))  16  0.0294  0.0018 (L=1,H=6,M=9)  -0.56  0.44  
[N](p[C]([C]([C][O])p[N](p[N,0]))p[N](p[N,0]([C])))  10  0.0293  0.0025 (L=3,H=3,M=4)  -0.93  0.54  
[N](p[C]([C]([C][O])p[N](p[N,0]))p[N]([C](p[C]p[C])p[N,
0]))  
10  0.0293  0.0025 (L=3,H=3,M=4)  -0.93  0.54  
[C]([C]([C][O])p[N](p[N])p[N](p[N]))  10  0.0293  0.0025 (L=3,H=3,M=4)  -0.93  0.54  
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Figure 3.19  Substructures showing positive influence on Kp,uu,brain. 
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Table 3.27 Top Negatively influential signatures for Kp,uu,brain. 
Signature  
Number  
of  
Occurenc
es  
Average  
gradient  
values  
Standard  
deviation 
(of  
gradient 
 values)  
Classification  
(3- class)  
Average  
Experiment
al  
Value  
Standard  
Deviation 
(of 
Experiment
al values)  
[C]([C][C][N]) 116 -0.0706 0.0106 
(L=67,H=16,M=33
) -1.35 0.69 
[C]([C](=[C])[N]([C])=[O]) 12 -0.0613 0.0048 (L=8,H=0,M=4) -1.65 0.43 
[O](=[C]([C](=[C])[N]([C]))) 12 -0.0613 0.0048 (L=8,H=0,M=4) -1.65 0.43 
[C](p[C](p[C])p[C](p[C][C])) 95 -0.0506 0.0096 
(L=37,H=17,M=41
) -1.12 0.67 
[N](p[C]([C]p[N])p[N](p[C])) 69 -0.0399 0.0021 (L=44,H=4,M=21) -1.41 0.47 
[C](p[C](p[C])p[C](p[C])[C]([N]=[O])) 24 -0.0384 0.0087 (L=15,H=2,M=7) -1.47 0.56 
[C]([C]p[N]p[N]) 75 -0.0375 0.0031 (L=45,H=6,M=24) -1.36 0.52 
[C]([C]([C][C][N])) 13 -0.0364 0.0171 (L=10,H=2,M=1) -1.56 0.79 
[C]([C]([C][C])) 11 -0.0361 0.0138 (L=7,H=0,M=4) -1.56 0.39 
[N]([C]([C])[C]([C])[C]([C][C])) 23 -0.0349 0.0085 (L=14,H=1,M=8) -1.46 0.44 
[C]([C](=[C]([C,0])[C](p[N]p[N]))=[N]([N]([C,0]))) 22 -0.0339 0.0029 (L=19,H=0,M=3) -1.67 0.32 
[C]([C](=[C]([C][C,0]))[N]([N](=[C,0]))=[O]) 22 -0.0339 0.0029 (L=19,H=0,M=3) -1.67 0.32 
[C]([C](=[C])[N]([N])=[O]) 22 -0.0339 0.0029 (L=19,H=0,M=3) -1.67 0.32 
[C]([C]([N]([N,0])=[O])=[C]([C](=[N,0])[C](p[N]p[N])))|0| 22 -0.0339 0.0029 (L=19,H=0,M=3) -1.67 0.32 
[N]([C]([C](=[C,0])=[O])[N](=[C]([C,0])))|0| 22 -0.0339 0.0029 (L=19,H=0,M=3) -1.67 0.32 
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Figure 3.20 Substructures showing negative influence to Kp,uu,brain. 
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3.10 Descriptor analysis for the individual components (Kp,brain, Vu,brain and 
fu,p) 
While the substructure analysis for Kp,uu,brain proved to be quite complex, it was attempted to 
do such an analysis on the individual models of Kp,brain, Vu,brain and fu,p using the RF VIP value 
analysis and the signature descriptor gradient analysis. 
3.10.1 RF VIP: 
Calculation of RF VIP values for the three component models Kp,brain, Vu,brain and fu,p produced 
results where some clearly vital descriptors came at the top positions. 
The table 3.28 shows the analysis on the Kp,brain model. The top descriptor in the list came up 
to be PSA which has been established as a very important determinant for the Kp,brain. There 
were also other descriptors based on hydrogen bonding properties in the list. 
 
Table 3.28 Top 15 Descriptors based on RF VIP for Kp,brain. 
Descriptor VIP   
PSA 0.013 
Van der Waals radius surface, summed over all N, O and attached hydrogens, 1-3 overlap 
correction. 
SAS_POL_AREA 0.012 Solvent accessible surface polar area. 
MM_VDW_EP_P_MEA
N 0.011 Mean of positive electrostatic potentials on Van der Waals surface. 
HBDmax 0.011 Highest free energy factor for H-bond donors according to Raevsky (HYBOT). 
MM_SAS_EP_P_SUM 0.011 Sum of positive electrostatic potentials on solvent accessible surface. 
MM_VDW_EP_P_SUM 0.01 Sum of positive electrostatic potentials on Van der Waals surface. 
HBD_Selma 0.01 Number of hydrogen bond donors. 
SPEC_SAS_NONPOL_A
REA 0.008 SAS_NONPOL_AREA / SAS_TOT_AREA. 
PAT 0.008 Number of polar atoms (O, N, S, P). 
MM_QO 0.008 Sum of atomic charges on O. 
HBsumTotal 0.008 Sum of donor and acceptor free energies according to Raevsky (HYBOT). 
MWPat 0.008 MW *Pat/AT_TOT Proportion of MW accounted for by the polar atoms (by number). 
SPEC_SAS_POL_AREA 0.007 SAS_POL_AREA / SAS_TOT_AREA. 
SPEC_SAS_HB_D_ARE
A 0.007 SAS_HB_D_AREA / SAS_TOT_AREA. 
MM_SAS_EP_N_SUM 0.007 Sum of negative electrostatic potentials on solvent accessible surface. 
 
On the other hand, for the parameter Vu,brain is highly dependent on the lipophilicity, ClogP 
scored the maximum VIP value, thus coming on top of the list (Table 3.29). This table clearly 
shows many lipophilicity related descriptors. 
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Table 3.29 Top 15 descriptors based on RF VIP for Vu,brain. 
Descriptor VIP   
ClogP 0.025 ClogP is a predicted octanol/water partition coefficient from Daylight/Biobyte 
ACDlogP 0.02 ACDlogP is calculated as the octanol/water partition coefficient for the neutral species. 
Motoc 0.019 Topological distance matrix based index related to ring structures. 
GClogP 0.019 Octanol/water partition coefficient based on Ghose/Crippen atom types 
VDW_NONPOL_AREA 0.017 Van der Waals non-polar surface area. 
NNlogP 0.017 
Octanol/water partition coefficient using a neural network approach based on Ghose/Crippen atom 
types 
SAS_NONPOL_AREA 0.016 Solvent accessible surface non-polar area. 
HuckelResEnergy 0.015 Huckel molecular orbitals, resonance energy. 
MinEV2 0.013 2nd smallest minimum eigenvalue from connectivity matrix, where diagonal has atomic weights. 
M1M 0.013 Moment of inertia along the first principal axis of the molecule. 
Kappa2 0.012 Topological index. 
MWNPat 0.011 
MW * NPat/AT_TOT Proportion of MW accounted for by the excess of non-polar atoms (by 
number) 
FractionIonized 0.011 (1 - FractionNeutral) 
VDW_AREA 0.011 Van der Waals molecular surface area. 
AromCount 0.011 Number of aromatic atoms. 
 
fu,p, a parameter that related to plasma protein binding is highly influenced by the charges and 
lipophilicity of the molecules, which is clearly seen in the results (Table 3.30). 
 
Table 3.30 Top 15 descriptors based on RF VIP for fu,p. 
Descriptor VIP  
Base 0.014 Presence of a basic function. 
POS_charges 0.0118 Number of basic groups likely to be ionised at pH 7.4. 
NNlogP 0.010 
Octanol/water partition coefficient using a neural network approach based on Ghose/Crippen atom 
types 
GClogP 0.010 Octanol/water partition coefficient based on Ghose/Crippen atom types 
Amine3 0.01 Number of tertiary amines. 
ClogP 0.01 ClogP is a predicted octanol/water partition coefficient from Daylight/Biobyte 
ACDlogP 0.008 ACDlogP is calculated as the octanol/water partition coefficient for the neutral species. 
CHARGES 0.008 POS_charges + NEG_charges. 
HOMO 0.008 Huckel molecular orbitals, Highest occupied molecular orbital energy. 
ACDlogD74 0.007 ACDlogD74 is calculated as the octanol/water distribution coefficient at pH 7.4. 
HuckelPiEnergy 0.007 Huckel molecular orbitals, pi electrons energy. 
PIAT 0.007 Number of pi atoms (number of atoms linked to double bonds + number of halogen atoms). 
AromCount 0.007 Number of aromatic atoms. 
MaxPosChargeGH 0.006 Maximum positive charge using the Gasteiger-Huckel partial charge equilibration. 
M1M 0.006 Moment of inertia along the first principal axis of the molecule. 
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3.10.2 Signature Descriptor 
In the signature descriptor analysis of Kp,brain, it was noticed that as expected the groups that 
increase lipophilicity like –CH3 , -Cl substitutions came up in the list of top 15 signatures 
positively influencing Kp,brain(Table 3.31). While groups like amides and ethers were seen in 
the negative influence (Table 3.32) which is due to their hydrogen bonding properties. 
However, some signatures representing aromatic aliphatic esters came up as positively 
influencing Kp,brain possibly due to their poor hydrogen bonding capacities. 
 
Vu,brain is mainly lipophilicity driven. Tertiary and secondary amines, lipophilic substitutions 
like sulphur, methyl groups were seen to influence Vu,brain positively (Table 3.33).  
As expected, ether and amides groups were frequently represented in the negative list (Table 
3.34).  
 
Since fu,p depends on the plasma protein binding, signatures representing groups that are vital 
for such interactions were observed in the analysis like the hydroxyl group, amides, ethers, 
long alkyl chains etc (Table 3.35 and 3.36). 
 
An effort has been made to interpret the machine learning models for Kp,uu,brain by calculating 
the decision function gradient for the descriptors. Some descriptors having large gradient 
values have been provided in the tables below. However, there is still a lack of understanding 
of existence of a clear trend in these descriptors.  In the future work, further exploration of 
the relationship between the descriptors and the Kp,uu,brain would be needed in order to 
improve the model interpretation. 
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Table 3.31 Top 15 positively influencing signatures for Kp,brain. 
Signature  Number of 
occurences 
Gradient 
Values  
Average Experimental  
Value  
Standard Deviation  
[C](p[C](p[N])p[N](p[C]))  14 0.1288 -0.82 0.80 
[C](p[C](p[C][C])p[C](p[C][C]))  23 0.1174 -0.15 0.95 
[C]([C]([C])[C]([C])[N]([C][C]))  14 0.1099 -0.48 1.08 
[O]([C][C])  236 0.0791 -0.85 0.79 
[C](p[C](p[C](p[C,0]))p[C](p[C](p[C,0])[Cl]))  156 0.0745 -0.97 0.65 
[C]([C]p[C](p[C])p[C](p[C]))  62 0.0722 -1.13 0.72 
[C]([C](p[C](p[C])p[C](p[C]))) 62 0.0722 -1.13 0.72 
[C]([N])  330 0.0648 -0.96 0.83 
[N](p[C](p[C])p[C](p[C][O]))  27 0.0639 -0.85 0.55 
[C](p[C](p[N](p[C,0]))p[N](p[C]([C]p[C,0])))  14 0.0639 -0.82 0.80 
[C]([C]([C])[C]([C][N]))  123 0.0637 -0.98 0.74 
[C](p[C](p[C](p[C,0]))p[C]([C]p[C](p[C,0])))  56 0.0627 -1.14 0.74 
[C](p[C](p[C]([C]p[C,0]))p[C](p[C](p[C,0][Cl])))  122 0.0624 -0.94 0.66 
[O]([C][C](p[C](p[C])p[N](p[C])))  41 0.0605 -0.85 0.56 
[O]([C][C](p[C]p[N]))  44 0.0593 -0.84 0.59 
 
Table 3. 32 Top 15 negatively influencing signatures for Kp,brain. 
Signature  Number of 
occurences 
Gradient 
Values 
Average  Experimental 
Value 
Standard 
Deviation  
[C]([C]([C][N])[O]([C]))  21 -0.1175 -1.16 0.66 
[O]([C]([C]([N,0]))[C]([C]([C][N,0])))  14 -0.1173 -1.12 0.66 
[C]([C][S])  35 -0.0777 -1.16 0.59 
[N]([C]([C]([C,0]))p[C]([C](p[C]p[C])p[N](p[N,1]))p[C](p[N,1][N]([C][C,0])))  23 -0.0749 -0.97 0.47 
[C](p[C](p[C](p[C,0]))p[C](p[N](p[C,0]))[C](p[N](p[N])p[N]([C]p[C])))  33 -0.0744 -1.15 0.54 
[C]([N]([C](=[C])[C]([C]=[O])))  31 -0.0742 -1.39 0.40 
[N]([C][C](=[C])[C]([C]=[O]))  31 -0.0742 -1.39 0.40 
[C](=[C][N])  58 -0.0729 -1.48 0.47 
[C]([S]([C]=[O]))  15 -0.0708 -1.61 0.24 
[C]([C](p[C](p[C])p[C](p[C]))p[N](p[N](p[C,0]))p[N]([C]p[C,0]([N])))  47 -0.0694 -0.89 0.63 
[C](p[C](p[C])p[C](p[C])[C]([N]=[O]))  45 -0.0683 -0.66 0.95 
[N]([C]([C]=[O]))  12 -0.0677 -1.13 0.79 
[C]([C]p[N]p[N])  303 -0.0672 -1.12 0.63 
[C]([C]([C]([C,0]))[C]([N]([C][C,0]))) 21 -0.0671 -0.91 0.58 
[N](p[C]([C]p[N])p[N](p[C])) 277 -0.0666 -1.14 0.60 
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Table 3.33 Top 15 positively influencing signatures for Vu,brain 
Signature  Number of occurences  Gradient Values  Average Experimental Value  Standard Deviation  
[C](p[C]p[C])  1014 0.1019 1.64 0.66 
[C]([C]([C]([C,0]))[N]([C,0][C](p[C]p[C])))  22 0.0905 2.21 0.63 
[S](p[C]p[C])  213 0.0815 1.86 0.75 
[C](p[C]p[N][O])  43 0.0805 1.24 0.73 
[S]([C][C])  38 0.0665 1.80 0.75 
[C]([C]([N]([C][C,0]))[N]([C][C]([C,0])))  30 0.0653 1.85 0.66 
[C](p[C](p[C])p[C](p[C])[Cl])  112 0.0652 1.79 0.73 
[Cl]([C](p[C](p[C])p[C](p[C])))  112 0.0652 1.79 0.73 
[N]([C][C])  572 0.0620 1.56 0.72 
[C](p[C]p[C][O])  502 0.0608 1.83 0.58 
[C]([C](p[C]p[C]))  161 0.0601 1.64 0.69 
[C]([C]([C])[C](p[C]p[C]))  48 0.0551 2.08 0.47 
[S](p[C](p[C](p[C])p[C](p[C]p[N,0]))p[C]([N]([C])p[N,0]))  118 0.0543 2.22 0.41 
[C](p[C]p[C]p[N])  217 0.0528 1.99 0.59 
[C](p[C]p[C][Cl])  319 0.0512 1.87 0.66 
 
Table 3.34 Top 15 negatively influencing signatures for Vu,brain. 
Signature  Number of occurences  Gradient Values  Average Experimental Value  Standard Deviation  
[C](p[C](p[C])p[C](p[C]))  439 -0.0838 1.43 0.64 
[C]([C]p[N]p[N])  125 -0.0786 1.13 0.50 
[N]([C]([C]([O,0]))[C]([C]([O,0]))[C](p[C](p[C])p[C](p[C][O])))  38 -0.0774 2.01 0.49 
[C](p[C]p[N])  365 -0.0743 1.30 0.63 
[C]([C][O])  460 -0.0739 1.59 0.67 
[C](p[C](p[C])p[C]([C]p[N]))  56 -0.0652 1.29 0.60 
[C]([C][N]=[O])  877 -0.0647 1.59 0.68 
[O](=[C]([C][N]))  877 -0.0647 1.59 0.68 
[N](p[C](p[C])p[C](p[C][C]))  53 -0.0625 1.24 0.41 
[C](p[C](p[C](p[C,0]))p[C](p[C](p[C,0])[C]([N]=[O]))[Cl])  46 -0.0615 1.90 0.51 
[C]([C]([C]([C,0]))[N]([C]([C])[C,0]))  28 -0.0591 2.13 0.50 
[C]([C]p[C]p[N])  260 -0.0590 1.37 0.60 
[C](p[C][C]p[N])  216 -0.0580 1.28 0.63 
[C](p[C](p[N](p[C,0]))p[C](p[C]([C]p[C,0])))  59 -0.0580 1.03 0.43 
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Table 3.35 Top 15 positively influencing signatures for fu,p 
Signature  Number of occurences  Gradient Values  Average Experimental Value  Standard Deviation  
[C](p[C]p[C])  1014 0.1019 1.64 0.66 
[C]([C]([C]([C,0]))[N]([C,0][C](p[C]p[C])))  22 0.0905 2.21 0.63 
[S](p[C]p[C])  213 0.0815 1.86 0.75 
[C](p[C]p[N][O])  43 0.0805 1.24 0.73 
[S]([C][C])  38 0.0665 1.80 0.75 
[C]([C]([N]([C][C,0]))[N]([C][C]([C,0])))  30 0.0653 1.85 0.66 
[C](p[C](p[C])p[C](p[C])[Cl])  112 0.0652 1.79 0.73 
[Cl]([C](p[C](p[C])p[C](p[C])))  112 0.0652 1.79 0.73 
[N]([C][C])  572 0.0620 1.56 0.72 
[C](p[C]p[C][O])  502 0.0608 1.83 0.58 
[C]([C](p[C]p[C]))  161 0.0601 1.64 0.69 
[C]([C]([C])[C](p[C]p[C]))  48 0.0551 2.08 0.47 
[S](p[C](p[C](p[C])p[C](p[C]p[N,0]))p[C]([N]([C])p[N,0]))  118 0.0543 2.22 0.41 
[C](p[C]p[C]p[N])  217 0.0528 1.99 0.59 
[C](p[C]p[C][Cl])  319 0.0512 1.87 0.66 
 
Table 3.36 Top 15 negatively influencing signatures for Vu,brain. 
Signature  Number of occurences  Gradient Values  Average Experimental Value  Standard Deviation  
[C](p[C](p[C])p[C](p[C]))  439 -0.0838 1.43 0.64 
[C]([C]p[N]p[N])  125 -0.0786 1.13 0.50 
[N]([C]([C]([O,0]))[C]([C]([O,0]))[C](p[C](p[C])p[C](p[C][O])))  38 -0.0774 2.01 0.49 
[C](p[C]p[N])  365 -0.0743 1.30 0.63 
[C]([C][O])  460 -0.0739 1.59 0.67 
[C](p[C](p[C])p[C]([C]p[N]))  56 -0.0652 1.29 0.60 
[C]([C][N]=[O])  877 -0.0647 1.59 0.68 
[O](=[C]([C][N]))  877 -0.0647 1.59 0.68 
[N](p[C](p[C])p[C](p[C][C]))  53 -0.0625 1.24 0.41 
[C](p[C](p[C](p[C,0]))p[C](p[C](p[C,0])[C]([N]=[O]))[Cl])  46 -0.0615 1.90 0.51 
[C]([C]([C]([C,0]))[N]([C]([C])[C,0]))  28 -0.0591 2.13 0.50 
[C]([C]p[C]p[N])  260 -0.0590 1.37 0.60 
[C](p[C][C]p[N])  216 -0.0580 1.28 0.63 
[C](p[C](p[N](p[C,0]))p[C](p[C]([C]p[C,0])))  59 -0.0580 1.03 0.43 
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4. CONCLUSION AND FUTURE PERSPECTIVES 
 
In a drug discovery project, it is very critical to determine whether or not a drug molecule 
will pass through the BBB. Computational prediction of such properties prove to be of great 
utility in reducing the time and resources spent by aiding in the early elimination of 
compounds possessing undesirable qualities. The work thus involved building a predictive 
model that can help in assessing BBB permeability properties of compound. 
Revisiting a previous in-house Kp,uu,brain model and extending the dataset along with applying 
newer techniques saw a further improvement in the performance, where the R
2
 increased to 
0.64 for the best consensus model. This model is composed of 5 different components (using 
different Machine learning algorithms and descriptors) and has a two-class accuracy of 84% 
along with the moderate class precision of 48%, in contrast to the 40% seen in the validation 
results. Here, we see a clear improvement in the overall predictive powers of the model, on 
the other hand, it can be noted that the model complexity has further increased. 
Conformal prediction applied on the SVM model with signature descriptor pointed to the 
possible noise in the experimental data by giving results that were not clearly interpretable. 
However, a consistency was always noted between the model performance, in terms of the R
2
 
and RMSE, and the interval length output by the conformal predictor. The Kp,uu,brain indirect 
model in this case gave a high interval length, also probably due to the formula used for 
calculating the Kp,uu,brain range not being very appropriate. The results from the conformal 
prediction for the Kp,uu,brain indirect can be further studied possibly by defining a more suitable 
equation for calculating the range. It is also important to note that the results from the 
conformal prediction might probably point to the unsuitability of its use with the dataset used 
in the study, as the dataset requires to agree with IID assumptions to be able to successfully 
apply Conformal prediction.  
Model interpretation involving understanding of the factors influencing the Kp,uu,brain values 
based on RF VIP values showed a consistency with previous studies by suggesting many 
descriptors related to topology and polarity as highly influential. The importance of these 
descriptors have been described previously. On the other hand, the substructure analysis 
using the signature gradient showed some unclear trends which still remain to be analyzed 
further. This reflects the fact that Kp,uu,brain is a parameter describing a highly complex 
process, making it difficult to have a clear understanding of concepts like the important 
substructures. Work will continue in an attempt to understand these factors. 
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